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ABSTRACT 
 
THE ROLE OF ARX IN SPECIFICATION AND MAINTENANCE OF 
PANCREATIC ISLET α-CELLS 
Crystal L. Wilcox 
Catherine L. May, Ph.D. 
 
Correct specification and maintenance of pancreatic islet cells is an intricate process.   
Previous studies have demonstrated the essential role transcription factors play in this 
process.  For islet glucagon-producing α-cells one such transcription factor is the 
aristaless-related homeobox gene (Arx).  Previous studies have demonstrated that Arx is 
necessary and sufficient for α-cell specification where ablation of Arx results in complete 
loss of the α-cell lineage and misexpression leads to conversion into an α-cell phenotype.  
However, the role of Arx in maintenance of α-cell fate as well the impact non-null 
mutations of Arx have on α-cell development has not been explored.  In this dissertation, 
I utilize mouse models and pancreatic analysis to address this question.  My results 
demonstrate that Arx is necessary to maintain α-cell fate during development as well as 
in the adult.  Furthermore, analysis of a non-null expansion mutation of Arx suggests dual 
roles for this factor during α-cell specification in activation of α-cell fate and repression 
of non-α-cell fate.  These findings expand the role of Arx in the islet α-cell as well as 
provide an attractive avenue for future therapies for type II diabetes. 
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CHAPTER I:  
 
INTRODUCTION 
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The pancreas is a two-component organ responsible for maintaining glucose 
homeostasis and digesting nutrients. 
 The pancreas is an organ situated between the stomach and intestine composed of 
three tissue types: exocrine, endocrine, and ductal [1].  The exocrine portion of the 
pancreas makes up the majority of pancreatic mass [2].  It is comprised of acinar cells, 
which secrete digestive enzymes utilized in the duodenum of the digestive tract [2]. The 
endocrine portion of the pancreas, organized into small spheres called Islets of 
Langerhans, is responsible for producing and secreting hormones responsible for glucose 
homeostasis [1]. The ductal system of the pancreas is a series of tubes that connects the 
exocrine acinar cells to the duodenum of the intestine [1]. 
During embryogenesis dorsal and ventral evagination of the foregut endoderm 
occurs resulting in the formation of the dorsal and ventral pancreatic buds [3].  This event 
takes place at approximately embryonic day (E)9.5 for the dorsal bud and a day later for 
the ventral bud (Fig 1.1) [4].  Initially, the pancreas grows as two separate buds 
influenced by distinct signals from the surrounding tissues and transcriptional regulators 
[4].  During mid-gestation, these buds undergo branching morphogenesis and 
differentiation to form the mature pancreas containing the three major cell types [4].  
Before birth, the ventral portion of the pancreas rotates around the gut to fuse with the 
dorsal portion, thereby forming the final pancreatic structure (Fig 1.1) [1].   
 Pancreatic development is organized into two transitions during embryogenesis 
(Fig. 1.1).  The primary transition begins with the budding of the dorsal pancreas around 
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E9.5 [3].  The initial set-up of the pancreatic epithelium defines this period [3].  The 
secondary transition occurs between E13.5 and E15.5 and is marked by a peak of 
endocrine and exocrine proliferation and expansion [3]. During this time the exocrine 
acinar cells expand exponentially and begin to produce digestive enzymes [3].  In the 
endocrine compartment, the secondary transition is when the principal endocrine cells are 
formed and migrate to form the Islets of Langerhans [3]. 
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Figure 1.1: Primary and Secondary Transitions of Pancreatic Development 
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Figure 1.1: Primary and Secondary Transitions of Pancreatic Development. A 
schematic diagram depicting embryonic pancreas development. Around E9.5 dorsal and 
ventral pancreatic buds develop from the foregut/midgut junction of the definitive 
endoderm.  The dorsal bud develops first, followed a day later by the ventral bud.  The 
initial budding, proliferation, and set-up of the pancreatic structure define the primary 
transition.  The secondary transition consists of a wave of exocrine and endocrine cellular 
proliferation.  Finally, at ~E18, the ventral bud rotates around the gut and fuses with the 
dorsal bud to create the final pancreatic structure. 
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The endocrine Islets of Langerhans produce and secrete hormones responsible for 
glucose homeostasis. 
 The Islets of Langerhans contain five cell types: α, β, δ, PP, and ε [1].  Murine 
islets are comprised of a core of insulin producing β-cells with a surrounding mantle of α-
, δ-, PP-, and ε-cells, which synthesize the hormones glucagon, somatostatin, Pancreatic 
Polypeptide, and ghrelin, respectively (Fig 1.2A) [1].   
 During the primary transition a few glucagon+ and insulin+ cells are present [5]. 
However, these cells do not contribute to the functional compartment of the endocrine 
pancreas [6].  The principal endocrine cells develop during the secondary transition.  All 
endocrine cells are derived from a common endocrine progenitor population that is 
Neurogenin3+ (Ngn3+) [7].   Endocrine cells, first formed in the developing pancreatic 
ducts, undergo an endoderm-mesoderm transition to migrate into the surrounding acinar 
tissue and form the Islets of Langerhans [7].  This process begins during the secondary 
transition and is completed within the first two weeks of life [7].   
 The endocrine pancreas is responsible for glucose homeostasis, which is achieved 
through the converse actions of β- and α-cells secreting the hormones insulin and 
glucagon, respectively [8].  After ingestion of food, blood glucose levels rise and β-cells 
begin to secrete insulin [8]. Insulin signals to the skeletal muscle and adipose tissue to 
metabolize and store glucose, removing it from the blood stream, and consequently 
reducing blood glucose levels (Fig 1.2B) [8].  Conversely, during a period of fasting, 
such as sleep, blood glucose levels fall [9].  To maintain blood glucose levels during a 
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fasted state, glucagon is secreted from the pancreatic α-cells [9].  Glucagon signals to the 
liver to break down stored glucose and release it into the blood stream through the 
process of gluconeogenesis and glycogenolysis, resulting in a rise in blood glucose levels 
[10].  Together, these two hormones maintain proper blood glucose homeostasis.   
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Figure 1.2: The Islets of Langerhans are composed of five different cell types and 
control blood glucose homeostasis. 
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Figure 1.2: The Islets of Langerhans are composed of five different cell types and 
control blood glucose homeostasis. (A): Murine Islets of Langerhans are comprised of 
five cell types: a core of insulin-producing β-cells (blue) with a surrounding mantle of 
glucagon-producing α-cells (red), somatostatin-producing δ-cells (purple), Pancreatic 
Polypeptide-producing PP-cells (green), and ghrelin-producing ε-cells (orange).  (B): The 
converse actions of glucagon-producing α-cells and insulin-producing β-cells maintain 
glucose homeostasis.  Under conditions of high blood glucose, β-cells secrete insulin, 
which causes uptake and storage of glucose and a concomitant decrease in blood glucose 
levels. Conversely, when blood glucose levels fall too low, α-cells secrete glucagon, 
resulting in the breakdown of stored energy and increased blood glucose levels.   
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Loss of normal glucose homeostasis results in the metabolic syndrome diabetes 
mellitus. 
 Diabetes mellitus is a metabolic syndrome characterized by the loss of normal 
glucose homeostasis leading to consistently elevated blood glucose levels, even during 
periods of fasting [11].  Clinically, there are two forms of diabetes, type I and type II.  
Type I, or juvenile diabetes, results from the loss of endocrine β-cells via an autoimmune 
attack [12]. Type II diabetes is the most common form of the disease and is the product of 
insulin resistance and β-cell dysfunction [12]. In type II diabetes, β-cells become 
exhausted and can no longer produce enough insulin to properly lower blood glucose 
levels [12].   
 In correlation with the rise in obesity, the incidence of type II diabetes over the 
past few decades has skyrocketed [13].  Currently, 8.3% of the United States population 
has been diagnosed with some form of diabetes, which translates into 25.8 million adults 
and children [13].  Furthermore, there are 1.9 million new cases each year [13]. Diabetes 
has a deleterious influence on overall health, including negative impacts on a patient’s 
vision (glaucoma and cataracts), circulation (hypertension and neuropathy), skin 
(infections and inflammation), mental health, hearing, teeth (gum disease), stomach 
(gastroparesis), and kidneys (ketoacidosis and nephropathy), as well as dramatically 
increasing risk of stroke and heart attack [13].  Overall, diabetes and its related 
complications cost the United States $245 billion in 2012, making diabetes a global 
health crisis [13].   
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 Recently, a new model underlying the clinical presentation of diabetes has been 
proposed.  This new mechanism focuses on a bihormonal view of the disease, 
encompassing not only β-cell exhaustion and lack of insulin release, but also α-cell 
dysregulation and over secretion of glucagon [10].  In this model, β-cell exhaustion leads 
to loss of proper signaling to glucagon-producing α-cells [10].  This results in 
deregulation of α-cells, over secretion of glucagon, and further increases in blood glucose 
levels [14].  Additionally, continual glucagon release makes attempts to reduce blood 
glucose levels less effective, further compounding the problem [14].   
The bihormonal view of diabetes suggests that loss of proper glucose homeostasis 
results from dysregulation of the entire endocrine pancreas, not just lost β-cell function 
and insulin secretion [10].  Thus, treatments aimed at increasing β-cell mass or function 
while decreasing α-cell mass/function would be extremely effective at obtaining blood 
glucose control [15].  Most therapies only focus on increasing insulin content, while 
largely ignoring the effect of glucagon in these patients, rendering current therapies 
largely ineffective [15].  Thus, novel treatments addressing both sides of the bihormonal 
theory of diabetes are essential. 
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Novel treatments for diabetes focus on in vivo replacement of β-cells. 
 Currently, exogenous insulin administration through daily subcutaneous injections 
is the most common treatment for Type I and II diabetes (Fig 1.3) [13].  While this 
treatment addresses the most pressing hallmark of diabetes, high blood glucose levels and 
reduced insulin secretion, it contains several inherent flaws.  First, exogenous 
administration of insulin does not contain the same degree of control as endogenous β-
cell sensing and insulin release.  This lack of control requires constant blood glucose 
monitoring to ensure adequate insulin is administered to control blood glucose levels 
[13].  Second, exogenous insulin administration places patients at risk for severe and 
potentially life-threatening periods of hypoglycemia [16].  If insulin levels are forced too 
high this could cause blood glucose levels to fall dangerously low.  Finally, exogenous 
insulin administration does not address the long-term problem of β-cell loss or 
dysfunction.  Continual adjustment of insulin administration and dosage is necessary to 
combat insulin resistance and deteriorating blood glucose homeostasis [13].  New 
treatments that provide a finer degree of control and are more suitable for long-term use 
are critical, given the large percentage of the world population that suffers from some 
form of diabetes. 
 A novel treatment for type II diabetes has recently moved into clinical 
development: islet transplantation.  Islets are isolated from multiple donors, pooled, and 
transplanted into the portal vein of the liver where the islets attach to the walls of the vein 
[17].  Clinical trials have demonstrated success at reducing blood glucose levels and 
improving diabetic patient outcomes utilizing this approach [17].  However, there are 
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multiple drawbacks to islet transplantation.  Islets, especially β-cells, are sensitive to the 
immunosuppressants necessary for this procedure [17].  Furthermore, studies have 
demonstrated that transplanted islets have a finite life span of only five years before a 
patient requires either supplemental therapy or another transplant [17].  Additionally, 
multiple donors (usually 2-3) are necessary to obtain enough islets for a successful 
transplantation [17].  Overall, the current state of islet transplantation deems it unfeasible 
for large-scale use in treating Type II diabetes.  New developments in prolonging islet 
life as well as improved harvesting methods might make this treatment a more attractive 
option in the future. 
 A different take on the concept of β-cell replacement is the use of embryonic stem 
cells (ESCs) or induced pluripotent stem cells (iPS) to generate β-cells in vitro.  ESCs are 
cells with unlimited differentiation potential originally derived from human blastocysts 
[18].  These cells are maintained in culture and, using the correct developmental signals, 
can be directed into any mature cell type [18].  Thus, ESCs can theoretically be used to 
create functional, mature β-cells [18]. In contrast to the finite supply available for islet 
transplantation, creation of new β-cells in a laboratory setting would yield a theoretically 
unlimited β-cell population and make transplantation procedures more feasible [18].   
A variation on this method is the use of induced pluripotent stem cells (iPS cells). 
iPS cells are mature cells that are converted back into a stem-like fate [19].  These iPS 
cells can then be differentiated into a different mature cell type using the same 
technology as for ESCs [19].  The benefit of using iPS cells over ESCs is that iPS cells 
can be made from non-pancreatic tissue from the donor and thus be matched to the 
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recipient, eliminating the need for harmful and expensive immunosuppressive therapies 
(Fig 1.3) [19].   
 These stem cell based therapies have multiple obstacles, including lack of cellular 
homogeneity, inability to correctly differentiate, and questions regarding patient safety 
[19].  Neither the ESC or iPS fields have been able to produce mature β-cells that 
correctly respond to insulin in an in vitro setting [19].  Studies that have managed to 
make β-like cells report very low yield of potential β-cells from the starting stem cell 
population [20]. In fact, the majority of cells created are not β-cells, but rather are some 
other pancreatic or endoderm cell [20].  Finally, even if mature β-cells can be produced, 
they will require years of testing to ensure these cells do not become malignant once 
transplanted into recipient tissue [19].  Overall, while promising, these therapies are most 
likely decades away from being a treatment option for diabetic patients in a clinical 
setting. 
 Another very attractive therapy for type I and II diabetes is the use of 
transdifferentiation to create new β-cells in vivo [19].  This treatment involves altering 
the identity of other endogenous cells, typically pancreatic cell types, into a β-cell fate 
either through the loss or misexpression of specific proteins [19].  In vivo and in vitro 
studies have demonstrated that pancreatic cell types are relatively plastic and can be 
directed into a β-like-fate [21].  With the development of the bihormonal theory of 
diabetes, use of endogenous α-cells to create new β-cells in vivo has become a very 
appealing option [19].  Transdifferentiation of α-cells would address the bihormonal 
theory of diabetes by decreasing the number of glucagon-producing α-cells while 
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increasing the number of insulin-producing β-cells.  This would provide an ideal long-
term therapy for type I and II diabetic patients (Fig 1.3). 
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Figure 1.3: Current and novel treatment options for Type I and II diabetes 
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Figure 1.3: Current and novel treatment options for Type I and II diabetes. Flow 
chart depicting current (left most red box) and novel treatments (middle and right-most 
red boxes) for type I and type II diabetes.  Current therapies focus on exogenous insulin 
replacement or boosting β-cell function (left most red box).  New therapies currently in 
clinical development include islet transplantation (right most red box).  Future therapies 
focus on the generation of new β-cells (center red box) either through ESC/iPS 
differentiation (left purple box) or transdifferentiation of other endogenous cell types 
(right purple box). 
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Transcription Factors Are Essential for Proper Pancreatic Endocrine Specification 
and Maintenance. 
 In order to develop novel therapies to treat diabetes, knowledge of normal 
endocrine cell development and maintenance is critical.  Decades of research have 
demonstrated that broadly expressed (i.e. Ldb1) and cell type specific (i.e. Pdx1, etc) 
transcription factors are essential for the proper specification and maintenance of 
pancreatic endocrine cells [2]. 
 Transcription factors are proteins that bind to DNA and activate or repress 
specific transcriptional programs [22].  In the endocrine pancreas, these factors are first 
expressed in Ngn3+ endocrine progenitors, in which they act to narrow and define cell 
fate [7].  In turn these transcription factors turn on other cell-type specific proteins, 
eventually leading to the correct transcriptional program for each discrete endocrine cell 
population (Fig 1.4A) [7].  The transcriptional control of pancreatic endocrine cell 
specification has been most extensively studied in β-cells.  Three examples of β-cell 
specific transcription factors that are essential for correct specification and/or 
maintenance are Pdx1, Pax4, and MafA (Fig 1.4B).  
 Pdx1 is one of the first transcription factors expressed in the embryonic pancreas, 
starting at approximately E8.5 [23].  Expression originates in the entire pancreatic 
epithelium, but is eventually restricted to β- and δ-cells where it is expressed in the 
mature pancreas [24].  Ablation of Pdx1 early in development results in agenesis of the 
pancreas (Fig 1.4B) [23].  Additionally, a β-cell specific ablation of Pdx1 during 
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development results in a drastic reduction in the number of β-cells [24].  Finally, in the 
mature pancreas Pdx1 is essential for proper maintenance of β-cell function [25].  
Ablation of Pdx1 in mature β-cells leads to loss of proper insulin signaling and 
eventually, apoptosis [25]. 
 Another transcription factor important in β-cell specification and development is 
Pax4. Pax4 expression is seen at E9.5 in both pancreatic buds, but is restricted to β-cells 
after E15 [26].  Ablation of Pax4 in the developing pancreas results in loss of β- and δ-
cells with a concomitant increase in α- and ε-cell fates (Fig 1.4B) [26].   
 One of the most important transcription factors for maintenance of endocrine β-
cells is MafA.  MafA is first expressed at E13.5 in insulin+ cells, and persists into 
postnatal and adult stages [27]. Ablation of MafA during embryogenesis does not have a 
profound impact on β-cell specification, likely due to upregulation of the closely related 
protein MafB (discussed later) [27].  However, MafA is directly responsible for the 
transcriptional regulation of insulin and other glucose-responsive genes [27].  Ablation of 
MafA in the mature β-cell results in loss of insulin biosynthesis and secretion (Fig 1.4B).  
Furthermore, studies have demonstrated that MafA is a very accurate barometer of β-cell 
activity status [27].  When internal glucose levels are too high, MafA expression is 
reduced and eventually lost, indicating β-cell dysfunction and loss of glucose 
homeostasis [27].   
 While the transcription factors described above are generally β-cell specific, there 
are several other factors equally important to β-cells expressed in multiple cell types.  
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Specifically, Nkx2.2 is a transcription factor that is expressed in all endocrine cell types, 
except δ-cells, starting around E9.5 [28].  Ablation of Nkx2.2 results in loss of β-, α-, and 
PP-cells with a concomitant increase in ε-cells (Fig 1.4B) [29].  Interestingly, in Nkx2.2 
null mice there is a population of immature β-cells that don’t express Glut2 or 
glucokinase (mature β-cell markers), but do express other markers of β-cells, suggesting 
Nkx2.2 is crucial for proper β-cell maturation [29].   
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MafB, Brn4, and Arx are α-Cell Specific Transcription Factors Necessary for 
Correct Specification. 
 Similar to endocrine β-cells, transcription factors are also important in α-cell 
specification and maintenance.  For many years the endocrine α-cell has not garnered as 
much attention as its neighbor, the β-cell.  However, since the proposal of the bihormonal 
theory of diabetes, a higher degree of attention has focused on understanding the α-cell 
and transcription factors important in its specification and maintenance.  Much is still 
unknown about the α-cell, including a list of important transcription factors similar to the 
list for β-cells.  Currently, only three α-cell specific transcription factors necessary for 
specification and maintenance have been identified: MafB, Brn4, and Arx. 
 MafB is first expressed at E10.5 in hormone-producing endocrine cells (both 
insulin+ and glucagon+) [30].  It is expressed in both α- and β-cells during embryogenesis, 
but is restricted to α-cells after postnatal day (P)14 [30].  Ablation of MafB during 
embryogenesis results in α- and β-cell maturation defects [31].  In a mouse model of 
MafB ablation the number of glucagon+ and insulin+ cells is drastically reduced, although 
total endocrine mass is unchanged [31].  The authors demonstrate that while immature α- 
and β-cells do exist, these cells cannot become physiologically functional (Fig 1.4B) [31].  
MafB continues to be expressed in adult α-cells from P14 onward, but a role for MafB in 
maintenance of α-cell fate has not yet been explored [30]. 
 Another α-cell specific transcription factor is Brn4.  Brn4 is exclusively expressed 
in endocrine α-cells beginning at E10 [32].  Ablation of Brn4 in mouse models does not 
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display a pancreatic phenotype, likely due to compensation by other factors [32].  Further 
studies have demonstrated that Brn4 binds to and regulates glucagon gene transcription in 
the endocrine α-cell (Fig 1.4B) [33]. 
 The last transcription factor important in α-cell specification is the aristaless-
related homeobox gene (Arx) [34].  Numerous studies have demonstrated that Arx is 
necessary and sufficient for proper specification of the endocrine α-cell, upon which I 
will expand further in the following section.  Arx appears to be an attractive target for 
future transdifferentiation studies exploring novel therapies for diabetic patients. 
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Figure 1.4: Transcription Factors are Necessary for Proper Endocrine Specification 
and Maintenance. 
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Figure 1.4: Transcription Factors are Necessary for Proper Endocrine Specification 
and Maintenance. (A): Schematic depicting how transcription factors narrow endocrine 
fate through multiple developmental stages.  Pdx1 expression defines pancreatic 
progenitor fate while Ngn3 expression restricts fate to the endocrine lineage.  Cell 
specific transcription factors are expressed in Ngn3+ endocrine progenitors and define 
fate for each endocrine cell lineage.  Many factors continue to be expressed after birth 
and play a role in maintenance of cell fate. (B): Table outlining transcription factors 
important for endocrine specification and maintenance.  Columns outline embryonic 
expression profile (2nd column from left), adult/mature expression profile (2nd column 
from right), and ablation phenotype (right most column).   
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Arx is necessary and sufficient for endocrine α-cell specification. 
 Arx is a paired homeodomain-containing transcription factor located on the X-
chromosome at Xp22.13 [35].  Arx contains a variety of previously classified domains 
including an aristaless domain, an octapeptide domain, three nuclear localization 
sequences (NLS), a central acidic domain, and four polyalanine tracts [36]. Although Arx 
contains activation (aristaless) and repression (octapeptide and polyalanine tract 4) 
domains, several studies have demonstrated it mainly acts through a repressive 
mechanism (Fig 1.5A) [37].  Furthermore, Arx has been shown to co-localize with the 
co-repressors Groucho/Tranducin-like enhancer 1 (Tle1) and C-terminal binding proteins 
(CtBPs) [37,38].  This colocalization increases Arx’s repressive ability in in vitro assays 
[37]. 
 Previous studies have demonstrated that Arx is necessary and sufficient for α-cell 
specification.  Global ablation of Arx results in complete loss of glucagon-producing α-
cells with a concomitant increase in β- and δ-cells, maintaining normal pancreatic 
endocrine mass [34]. Ablation of Arx in pancreatic or endocrine progenitors demonstrates 
similar results, indicating this defect occurs in endocrine cell development (Fig 1.5B) 
[39].  Arx is Ngn3-dependent, and is first expressed in Ngn3+ endocrine progenitors [34].   
After specification, Arx becomes restricted to glucagon+ cells, where it is maintained into 
postnatal life [34].  While it has been proposed that loss of Arx leads to respecification of 
presumptive α-cells into β- and δ-cell fates, lineage tracing has not been performed to 
validate this model.  Arx is also sufficient to specify an α-cell fate.  Forced misexpression 
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of Arx in the developing pancreas or islets results in the conversion of β- and δ-cells into 
an α- and PP-cell fate (Fig 1.5B) [40].  
 Contrary to pancreatic Arx ablation, loss of the β-cell transcription factor Pax4 in 
the developing pancreas results in loss of β- and δ-cells and a concurrent increase in α- 
and PP-cells (described above) [26].  Work examining the opposing roles of Arx and 
Pax4 in endocrine specification has demonstrated that these two factors negatively 
regulate each other through direct DNA binding and co-repression [34].  Loss of Arx 
results in a significant upregulation of Pax4 while in Pax4 mutant mice the converse is 
true [34].  These data suggests that Arx and Pax4 help control the proper specification of 
α- and β-cells through a dual repression model. 
 The interaction of Arx with other endocrine transcription factors has also been 
explored, including the interaction between Arx and Nkx2.2.  Mastracci and colleagues 
demonstrated that loss of both Arx and Nkx2.2 causes an increase in ε-and δ-cells at the 
expense of α- and β-cell populations, which are completely lost in this model [41]. 
However, the increase in ε-cell number does not correspond to increased ghrelin 
transcript levels [41].  Furthermore, double mutants harbored a ghrelin+/somatostatin+ 
endocrine population not observed in controls [41]. Finally, although ablation of Nkx2.2 
alone results in a drastic decrease in the number of PP-cells, this cell population is 
restored in the double mutant mice [41].  Together these data demonstrates that there is a 
novel interaction between Arx and Nkx2.2 that helps regulate endocrine cell fate and 
specification.  Future studies examining the interaction between different transcription 
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factors will help expand and clarify this as well as other interactions necessary for 
endocrine cell fate specification and maintenance. 
 Together these previous studies show that Arx is necessary and sufficient for 
proper α-cell specification in the developing pancreas.  While the role of Arx in 
specification has been described, a possible role in cell fate maintenance has not yet been 
examined. Previous studies examining the role of the DNA methyltransferase, Dnmt1, in 
adult β-cell maintenance suggests that such a role could exist [42].  Loss of Dnmt1 results 
in progressive loss of DNA methylation, derepression of Arx, and transdifferentiation of 
β-cells into a glucagon+ α-cell fate [42].  These data suggest that similar to its role during 
embryogenesis, Arx is required for maintenance of α-cell fate in the adult pancreas.   
 Studies examining the role of Arx after specification are essential to determine a 
potential role for Arx in maintenance of endocrine α-cell fate.  Additionally, these studies 
will be helpful in examining the possibility of using mature endogenous α-cells in 
transdifferentiation experiments for novel treatments for type I and II diabetes. 
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Figure 1.5: Arx is a homeodomain-containing transcription factor necessary for the 
correct development of multiple tissue types 
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Figure 1.5: Arx is a homeodomain-containing transcription factor necessary for the 
correct development of multiple cell types. (A): Diagram outlining the domain 
structure of the Arx protein.  Arx contains an octapeptide domain, three nulclear 
localization sequences, four polyalanine tracts, an acidic domain, a homeodomain, and an 
aristaless domain. (B): Table outlining the role of Arx in the development of multiple 
tissue types.  Columns depict organ, model utilized, and resulting phenotype (from left to 
right).   
  
  
30 
Arx plays diverse roles in the development of multiple tissues.  
 While the role of Arx in the developing endocrine pancreas has been described, 
Arx is also expressed in a variety of other tissues including the digestive tract, skeletal 
muscle, testis, and brain [43].  The role of Arx in these other tissues has also been 
examined (Fig 1.5B).  In the digestive tract, ablation of Arx results in loss or severe 
reduction of several enteroendocrine cell populations including gastrin-, glucagon/GLP-
1-, CCK-, and secretin-producing cell populations with an increase in somatostatin-
expressing cells [44].  The role of Arx in the muscle and testis has also been described.  
During myogenesis (the development of muscle fibers) Arx acts as a positive regulator 
through its association with Mef2C and MyoD [45]. In testis development, ablation of 
Arx results in a drastic decrease in Leydig cell number due to defects in Leydig 
progenitor cells (Fig 1.5B) [46].   
 Finally, the role of Arx in neuronal development has been extensively described. 
Arx is first detected at the 3-somite stage [47].  After the 10-somite stage, it is confined to 
an area in the anterior neural plate where it is expressed throughout the telencephalic 
structures, including the ganglionic eminence, cerebral cortex, and hippocampus [48].  
Arx null mice die within a day of birth and display severe neuronal defects [49].  
Phenotypically, Arx null mice have smaller brains, olfactory bulbs, and testes [49].  
There are multiple developmental problems that are responsible for the observed 
phenotypes. Defects exist in tangential migration from the medial ganglionic eminence to 
the cortex, in radial and tangential migration in the striatum, radial migration in the 
cortex, cholinergic neuronal differentiation, and development of GABAergic interneurons 
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[49].  These defects result in a thickened striatum, thinner cortical plate, lissencephaly, 
and severe loss of inhibitory GABAergic interneurons [49].  When taken together, these 
data demonstrates that Arx plays multiple roles in neuronal development, including 
patterning, proliferation, migration, differentiation, and axonal outgrowth and 
connectivity (Fig 1.5B) [47].  
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Mutation of Arx results in a spectrum of human mental disorders. 
 Similar to mouse models, mutation of ARX in human patients results in several 
neurological disorders [50].  X-linked mental retardation (XLMR) is a heterogeneous 
group of disorders that result from mutations in genes located on the X-chromosome [50].  
XLMR dominantly affects male patients with some clinical defects reported for 
heterozygous females [50].  Mutations in ARX contribute significantly to this group of 
disorders.  ARX mutations and the associated clinical disorders can be placed on a 
spectrum, where more severe mutations result in more severe clinical outcomes and vice 
versa [50].  This spectrum demonstrates a striking and unique genotype-phenotype 
correlation, suggesting that ARX is directly responsible for the clinical presentations of 
these patients [50].   
 The most severe ARX-related disorder, X-linked lissencephaly associated with 
abnormal genitalia (XLAG), is associated with null and missense mutations of ARX [47].  
XLAG patients present with lissencephaly, agenesis of the corpus callosum, neonatal-
onset intractable epilepsy, severe hypotonia, ambiguous genitalia, and death within the 
first few months of life [51].  The clinical presentation of XLAG patients closely mirrors 
that of Arx null mice, potentially allowing scientists to use Arx mouse models to develop 
treatments for patients affected by ARX-related disorders [52]. 
 While XLAG mutations are on the most severe end of the ARX-disorder 
spectrum, the most common mutation is expansion of the first two polyalanine tracts of 
ARX [53].  Expansion of the first polyalanine tract by an additional seven alanines is 
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associated with the clinical disorder West syndrome, or infantile spasms (ISSX) [54].  
Patients suffering from West syndrome present with infantile spasms, hypsarrythmia, and 
mental retardation; however, they do not usually have brain malformations 
(lissencephaly), and also have a longer life expectancy than XLAG patients [54]. 
 To explore the mechanism behind the distinct differences in phenotype between 
XLAG-like mutations of ARX and the polyalanine expansion of ARX found in West 
syndrome, mice with a West syndrome expansion mutation were created [55,56].  Mice 
with an expansion mutation of Arx are born in normal Mendalian ratios and have brains 
that appear normal in size and gross morphology, unlike Arx null mice [55,56].  
However, mutant mice do have seizures, and die within six months of birth [55].  
Interestingly, GABAergic progenitor radial migration, which is absent in Arx null mice, 
appears normal in Arx expanded mice [55]. In contrast, tangential migration is lost, 
similar to the phenotype reported in the Arx null model [55].  Mechanistic studies behind 
these phenotypes demonstrate selective derepression of a subset of Arx targets in the 
polyalanine expansion mutant [57].  The authors attribute this selective derepression to 
loss of proper association with a subset of co-repressors [57].  Specifically, an expanded 
Arx demonstrated reduced, but not absent, association with Tle1 [57]. These studies 
demonstrate that expansion of Arx results in context specific defects due to selective loss 
of association with co-repressors.  
 Recently Itoh and colleagues explored the pancreatic phenotype in an ARX-null 
XLAG patient [58].  Interestingly, they demonstrated that similar to Arx null mice, 
human patients with null mutations in ARX have a complete loss of endocrine α-cells 
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[58].  This study demonstrates that, similar to neuronal studies, Arx null mice and XLAG 
patients display surprisingly similar pancreatic phenotypes.  However, the question of 
whether, similar to the brain, there is a genotype-phenotype correlation associated with 
ARX/Arx mutation severity and the specification and maintenance of endocrine α-cells 
remains unanswered.  Future studies using non-null Arx mutations are necessary to study 
this potential correlation.  Furthermore, any impacts observed might lead to treatments 
for Arx-related disorders, as well as type I and II diabetes mellitus. 
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Summary and Specific Aims 
 Understanding endocrine α-cell specification and maintenance is essential to 
provide knowledge in designing novel treatments type I and II diabetes.  The 
homeodomain-containing transcription factor, Arx, has been shown to be necessary and 
sufficient for α-cell fate specification [34,40].  However, Arx continues to be expressed 
in the mature α-cells and therefore could play an additional role in α-cell maintenance 
throughout life[34]. 
 Additionally, neuronal studies on the role of Arx in proper migration and 
development of interneurons, and the human pathologies associated with different forms 
of ARX mutations, have demonstrated a unique genotype-phenotype correlation [47].  
Arx null mice and XLAG patients demonstrate strikingly similar pancreatic phenotypes, 
namely a complete loss of endocrine α-cells [58].  Exploration of non-null Arx mutations, 
and the resulting impact on endocrine α-cells, will provide further information on proper 
endocrine specification and maintenance as well as whether a genotype-phenotype 
severity correlation exists in the pancreas as it does in the brain.   
 The following chapters in my thesis aim to expand the knowledge of the role of 
Arx in the endocrine α-cell.  The goal of these experiments is to (1) determine the role 
of Arx in maintenance of mature α-cell fate and (2) describe the effect a non-null 
Arx mutation has on α-cell specification and maintenance.  These results will 
demonstrate the role of Arx in maintenance of α-cell fate, as well as provide a better 
understanding of how a non-null Arx mutation impact α-cell development.  
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CHAPTER II: 
 
The Role of Arx in the Maintenance of Islet α-Cell Fate 
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Abstract 
The specification and differentiation of pancreatic endocrine cell populations (α-, β-, δ, 
PP- and ε-cells) is orchestrated by a combination of transcriptional regulators.  In the 
pancreas, Aristaless-related homeobox gene (Arx) is expressed first in the endocrine 
progenitors and then restricted to glucagon-producing α-cells.  While the functional 
requirement of Arx in early α-cell specification has been investigated, its role in 
maintaining α-cell identity has yet to be explored. To study this later role of Arx, we have 
generated mice in which the Arx gene has been ablated specifically in glucagon-
producing α-cells.  Lineage-tracing studies and immunostaining analysis for endocrine 
hormones demonstrate that ablation of Arx in neonatal α-cells results in an α-to-β-like 
conversion through an intermediate bihormonal state. Furthermore, these Arx-deficient 
converted cells express β-cell markers including Pdx1, MafA, and Glut2. Surprisingly, 
short-term ablation of Arx in adult mice does not result in a similar α-to-β-like 
conversion.  Taken together, these findings reveal a potential temporal requirement for 
Arx in maintaining α-cell identity.  
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Introduction 
During development, the pancreas organizes into two distinct compartments: 
the exocrine acinar cells, which secrete digestive enzymes, and the hormone producing 
endocrine cells organized into islets of Langerhans [1].  These islets contain a core of 
insulin-producing β-cells with a surrounding mantle of α, δ, ε, and PP-cells, which 
produce the hormones glucagon, somatostatin, ghrelin, and pancreatic polypeptide, 
respectively [2].  Islet β- and α-cells are the two key endocrine cell populations involved 
in maintaining glucose homeostasis [3]. Disruption of this homeostasis through β-cell 
loss or dysfunction leads to diabetes mellitus, a common metabolic disorder manifested at 
all ages.   
Given the limited supply of functioning β-cells in diabetics, one potential 
treatment avenue is cell-replacement therapy [4].  Considerable effort has been invested 
in identifying alternative β-cell sources through either directed differentiation from 
embryonic/induced pluripotent stem cells or reprogramming from other differentiated cell 
types [5].  Due to the close lineage relationship between α- and β-cells, the 
reprogramming potential of an α-cell to adopt a β-cell fate has been recently investigated 
[3].  In one study, new β-cells were generated from glucagon-producing α-cells through a 
glucagon+insulin+ bihormonal intermediate state after a near-total β-cell loss [6].  
Moreover, an α-to-β-cell lineage conversion was observed when Pax4, a pro-β-cell 
transcription factor, was expressed in pancreatic endocrine progenitors or α-cells [7]. 
 Similarly, forced expression of Pdx1 in endocrine progenitors leads to an increase in β-
cells and a decrease in α-cell number [8].  Although the α-cell population is mostly post-
mitotic, these studies collectively illustrate that α-cell fate can be plastic and is able to be 
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reprogrammed to adopt β-cell fate. However, the extent of this plasticity during different 
stages of an animal’s life is currently unknown.   
One transcription factor capable of altering plasticity in endocrine cells is the 
Aristaless-related homeobox gene (Arx). In the mouse pancreas, Arx is expressed in a 
subset of endocrine progenitors and then restricted to glucagon-producing α-cells where it 
is expressed throughout the life of the animal [9,10].  When misexpressed in the 
developing pancreas, Arx is sufficient to force endocrine progenitors or β-cells to adopt 
an α-cell fate [11]. These results demonstrate that Arx is sufficient for β-to-α-cell 
reprogramming during development.   
Although much is known regarding factors necessary and sufficient for endocrine 
development, the factors required to maintain the identity of mature α-cells during 
different stages are less clear.  Mice with Arx null mutations in the germ-line, pancreatic 
progenitors, or endocrine progenitors all display a complete loss of α-cells with a 
concurrent increase in β- and δ-cells in the pancreas [9,10,12].  Moreover, α-cell loss has 
been reported in patients with null mutations in ARX [13].  However, none of the existing 
mouse models are suitable for determining the function of Arx in maintaining (as opposed 
to establishing) mature α-cell identity.  Further, lineage-tracing experiments have not yet 
been performed to determine if loss of Arx leads directly to an α-to-β-cell conversion. 
Here we show that Arx is required for α-cell lineage maintenance in the neonatal 
pancreas, but not in the adult pancreas.  During the neonatal period, ablation of Arx 
results in loss of glucagon expression and activation of insulin and β-cell markers 
through an insulin+glucagon+ bihormonal intermediate. In contrast, short-term Arx 
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ablation in the adult pancreas does not result in either a loss of glucagon expression or an 
activation of β-cell marker expression. These data suggest that Arx may act in a stage- 
and context-specific manner in maintaining α-cell identity and reveal potential 
differential plasticity between fetal and adult α-cells. When taken together, these findings 
have important implications for the potential use of α-cells for the purpose of β-cell 
replacement therapy. 
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Results 
Arx removal in neonatal glucagon-producing cells. 
Arx is expressed in endocrine progenitors, α-cell precursors, and mature 
glucagon-producing cells of the pancreas [9,10].  To investigate its role in the neonatal α-
cell, we generated mice with Arx ablation in glucagon+ cells (ArxL/Y  or ArxL/L;Glucagon-
Cre; referred to as GKO hereon). First, a Rosa-YFP reporter was used to assess the Cre-
mediated recombination efficiency in our GKO model.  In P5 control mice (including 
Arx+/Y ;Glucagon-Cre, Rosa-YFP and Arx L/+ or +/+; Glucagon-Cre;Rosa-YFP), Arx 
expression was found in all glucagon+ cells; however, only 13% of glucagon+ cells co-
expressed Arx and YFP (Fig. 2.1A, C; white bar in control).  All male and female control 
animals utilized in these experiments were phenotypically identical according to their 
islet morphology and were compared to their sex-matched GKO animals. These 
observations indicate a low Cre-mediated recombination rate, which is in agreement with 
what others have previously reported using this Glucagon-Cre transgenic mouse [19].  In 
GKO;Rosa-YFP mutant mice, Arx protein was removed in all glucagon+YFP+ cells, 
which equated to about 12% of glucagon+ cells (Fig. 2.1B, C; grey bar in GKO).  This 
result suggests that YFP expression faithfully marks cells that have undergone Arx 
ablation. The low Cre-mediated recombination frequency was also observed in P21 
animals (Fig. 2.2 and data not shown). Real-time PCR analysis from P5 and P21 animals 
further showed Arx mRNA levels were decreased by 20% and 50% in GKO animals, 
respectively, although not significantly (Fig. 1D).  In addition, in P5 control animals, 
while 90% of YFP+ cells co-expressed glucagon, approximately 10% of the YFP+ cells 
  
were positive for insulin staining due to some leakiness of the Cre (see b
not shown). 
Figure 2.1: Arx is specifically ablated in YFP
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Figure 2.1: Arx is specifically ablated in YFP+ α-cells of GKO;Rosa-YFP mice.  P5 
pancreatic sections were stained for glucagon (blue), Arx (red), and YFP (green).  (A): 
Arx is expressed in all glucagon+ cells in control;Rosa-YFP pancreata. A subset of 
glucagon+Arx+ cells is YFP+. (B): In GKO;Rosa-YFP animals, there is a subset of 
glucagon+ cells that express YFP.  These YFP+ cells have lost Arx expression. Scale bar 
represents 25µm. (C): Quantitative analysis of Arx and YFP expressing cells within 
glucagon+ population in P5 animals. Over 500 total glucagon+ cells were counted with 
three mice per group used. Error bars represent standard error of the mean with p-value 
indicated. N.S: not significant.  (D): Quantitative PCR analysis for Arx mRNA in total 
pancreata at P5 and islets from P21 control and GKO animals.  Control mRNA level was 
set at one fold ± standard error of the mean.  Male and female control and GKO animals 
(n≥3) were sex-matched for all analyses.  
  
  
Figure 2.2: Arx is specifically ablated in P21 
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Figure 2.2: Arx is specifically ablated in P21 α-cells by Glucagon-Cre with Arx-
deficient cells expressed YFP.  Pancreata were stained for glucagon (blue), Arx (red), 
and YFP (green).  (A): Arx is expressed in all glucagon+ cells in control;Rosa-YFP 
pancreata. (B): In GKO;Rosa-YFP animals, Arx is ablated in all YFP+ cells.  Male and 
female GKO mice (n≥3) were analyzed and compared to their sex-matched controls. 
Scale bar represents 50µm. 
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Arx ablation in the GKO mice results in an emergence of glucagon+ insulin+ co-
expressing cells. 
To determine whether loss of Arx in the α-cells of GKO mice may have resulted 
in a change of cell fate in a small subset of cells, we performed double immunostaining 
for glucagon and other endocrine hormones. Given that only 12% of the glucagon-
producing cells have lost Arx expression, we did not expect to observe any significant 
changes in the number of glucagon cells or the localization of these cells in P5 GKO 
mice.  Indeed, immunostaining analyses confirmed this anticipated result (Fig. 2.3A-H). 
Real-time PCR analysis also revealed no significant changes in the mRNA levels of 
glucagon transcript between control and GKO mice (Fig. 2.3I).  Although hormone cell 
numbers were not significantly altered, close examination revealed a small population of 
glucagon+insulin+ bihormonal cells in the pancreas of GKO mice (Fig. 2.3B). These 
bihormonal cells were only found in the GKO mice.  There was no overlap or significant 
differences in the expression of glucagon with somatostatin or PP between P5 GKO and 
control mice (Fig. 2.3C-F).  Endocrine cells expressing glucagon and ghrelin have been 
reported in the developing and neonatal pancreas [20,21,22].  The number and location of 
these glucagon+ghrelin+ cells were comparable between P5 control and GKO mice (Fig. 
2.3G-H).  Real-time PCR analysis did not reveal any significant changes in hormone 
expression between P5 control and GKO animals (Fig. 2.3I-L). Together, these data 
indicate that loss of Arx in glucagon+ cells results in misexpression of the β-cell hormone 
insulin in glucagon+ α-cells. 
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To determine the fate of this bihormonal population we evaluated glucagon, 
insulin, somatostatin, PP, and ghrelin expression in the pancreata of P21 control and 
GKO mice by immunostaining.  Again, there was no significant change in the cell mass 
or distribution associated with these endocrine populations (Fig. 2.4A-B).  Interestingly, 
while a few glucagon+insulin+ cells could still be found in the P21 GKO mice, the 
frequency of this bihormonal population was dramatically reduced by this age relative to 
P5. Instead, many of the remaining bihormonal cells in P21 GKO mice have reduced 
glucagon staining in cells readily expressing insulin (Fig. 2.4A-B).  These cells are likely 
in the later stage of their α-to-β-like cell fate conversion. These observations suggest that 
upon ablation of Arx, insulin expression is activated in the glucagon-producing α-cell, 
which then gradually loses glucagon expression.  Finally, we evaluated mRNA levels for 
β-cell (Pdx1 and Nkx6.1) and α-cell (MafB and Brn4) markers in the islets isolated from 
P21 control and GKO mice. From the real-time PCR analysis, we observed a significant 
upregulation of Pdx1 mRNA and an upward trend of Nkx6.1 levels (Fig. 2.4J).  
Conversely, we detected a significant reduction in Brn4 with a small downward trend in 
MafB expression (Fig. 2.4J).  While the significant changes in the mRNA levels of Pdx1 
and Brn4 data are surprising in the context of the small changes in hormone expression, 
this result could be due to direct Arx regulation.  Arx could potentially directly repress 
Pdx1 and activate Brn4, which would result in a drastic increase of Pdx1 (and resulting 
decrease of Brn4) upon Arx ablation.  When taken together, these data suggest that 
glucagon-producing cells require Arx to maintain α-cell identity and repress β-cell 
markers during neonatal life. 
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Figure 2.3: Loss of Arx in glucagon+ cells results in the appearance of a 
glucagon+insulin+ population.   
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Figure 2.3: Loss of Arx in glucagon+ cells results in the appearance of a 
glucagon+insulin+ population. (A-H): P5 control and GKO pancreata were stained for 
glucagon (green), insulin (red; A, B), somatostatin (Sst; red; C, D), PP (red; E, F), and 
Ghrelin (red; G, H). Glucagon+insulin+ cells are the only bihormonal population unique 
to GKO animals (B, D, F).  Glucagon/ghrelin coexpressing cells are both found in control 
and GKO animals (G, H). Male and female control and GKO animals (n≥3) were sex-
matched for all analyses. Scale bar denotes 25µm. (I-L): Quantitative PCR analysis 
examining glucagon (I), insulin (J), somatostatin (K), and PP (L) gene expression in P5 
control and GKO animals.  Control mRNA level was set at one fold ± standard error of 
the mean. For all GKO and control groups, at least 3 biologic replicates were performed.  
  
  
Figure 2.4: Loss of glucagon
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+insulin+ cells in P21 GKO animals.
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Figure 2.4: Loss of glucagon+insulin+ cells in P21 GKO animals. (A-H): 
Immunostaining for glucagon (A-H), insulin (A-B), somatostatin (C-D), PP (E-F), and 
ghrelin (G-H) in P21 control and GKO animals with merged images shown. Glucagon 
positive cells do not overlap with insulin (A, B), somatostatin, (C, D) or PP (E, F).  
Ghrelin is no longer expressed at P21 (G, H).  (I): Total insulin, glucagon, somatostatin, 
and PP cell mass in the pancreata of P21 control and GKO mice. Male and female GKO 
mice (n≥3) were analyzed and compared to their sex-matched controls.  Scale bar denotes 
25µm.  (J): Quantitative PCR analysis for P21 control and GKO islets for β-cell markers 
Pdx1 and Nkx6.1 and α-cell markers MafB and Brn4. “*” denotes p<0.05. Error bars 
represents standard error of the mean. 
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Arx-deficient cells fail to maintain α-cell identity 
To directly determine the origin of the glucagon+insulin+ cells seen in P5 GKO 
mice, lineage-tracing studies were performed in P5 GKO mice. Triple-immunostaining 
for glucagon, insulin, and YFP were performed in the pancreas of control;Rosa-YFP and 
GKO;Rosa-YFP mice.  YFP expression was detected in only a subset of glucagon-
producing cells at P5 (Fig. 2.5A-B), due to the low frequency of the Cre-mediated 
recombination in the Glucagon-Cre transgenic mice (Fig. 2.1).  The majority of YFP+ 
cells in the P5 control mice expressed glucagon (Fig. 2.5A, E and F) though a very small 
number of insulin-producing cells positive for YFP expression were found (blue), 
demonstrating relatively high, though not 100%, fidelity of the Cre-mediated 
recombination (Fig. 2.5E and F).  In P5 GKO mice, we noticed an emergence of 
glucagon+insulin+YFP+ (purple) cells and an increase in the number of insulin+YFP+ 
(blue) cells while the number of glucagon+YFP+ (red) cells was reduced compared to 
controls (Fig. 2.5A-B, E and F).  
To follow up with our previous observations that the glucagon+insulin+ cell 
number has dramatically reduced by P21, we evaluated the pancreata of control;Rosa-
YFP and GKO;Rosa-YFP mice at P21 for glucagon, insulin, and YFP expression.  
Interestingly, corresponding to the previously described disappearance of bihormonal 
cells by P21 (Fig. 2.4A-B), the majority of YFP+ cells in GKO;Rosa-YFP pancreata at 
this stage were insulin+ (blue) with only a small percentage of YFP+ cells expressing both 
insulin and glucagon (purple) or glucagon alone (red) (Fig. 2.5C-D and G). These data 
demonstrate that Arx loss in glucagon-producing α-cells leads to a failure in maintaining 
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α-cell identity and a conversion to a β-cell-like fate. Taken together, these lineage-tracing 
data indicate that the loss of neonatal Arx in glucagon-producing cells results in a cell fate 
conversion from a glucagon+ α-cell into an insulin+ β-cell-like fate through a bihormonal 
intermediate.   
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Figure 2.5: Lineage tracing studies demonstrate that Arx ablated α-cells become 
glucagon+insulin+ at P5 then insulin expressing at P21. 
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Figure 2.5: Lineage tracing studies demonstrate that Arx ablated α-cells become 
glucagon+insulin+ at P5 then insulin expressing at P21. (A-D): Triple immunostaining 
for glucagon (red), insulin (blue), and YFP (green) in control;Rosa-YFP and GKO;Rosa-
YFP pancreata at P5 and P21. YFP+ cells in P5 or P21 control;Rosa-YFP animals are 
positive for glucagon (A and C;). “*” denote insulin cells that are negative for glucagon 
or YFP expression (A and C; *) Glucagon+insulin+YFP+ cells are found in P5 GKO 
animals (B; ), but rarely in controls (A).  YFP+ cells are positive for glucagon in control 
P21 pancreata (C; ) but insulin+ in P21 GKO pancreata (D; ). (E): Schematic outlining 
cell populations resulting from lineage-tracing and immunostaining analysis. (F, G): 
Quantification of hormone expression in YFP+ cells at P5 (F) and P21 (G).  At P5 and 
P21, over a total of 10,000 cells were counted from 3-5 animals per group. Out of the 
10,000 cells counted, approximately 1,000 cells were YFP+.  Each category was 
calculated and presented as a percentage of total YFP+ cells per animal and then 
averaged. Error bars are denoted as standard error of the mean with significance (p≤0.05) 
between each color denoted with “*”, “”, and “”. Male and female GKO mice (n≥3) 
were used for all analysis and compared to their sex-matched controls. Scale bar 
represents 25µm. 
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Markers associated with mature β-cells are activated in Arx-deficient YFP+ cells.  
To further examine how closely these newly converted β-like-cells were to true β-cells, 
expression of several known β-cell markers including Glut2, MafA, and Pdx1 were 
examined in control;Rosa-YFP and GKO;Rosa-YFP mice at P5 and P21. In P5 
GKO;Rosa-YFP animals, there was a significant increase in the number of YFP+ cells 
coexpressing Glut2, MafA, or Pdx1 (Fig. 2.6B, D, F, G, I, K).   Similar increases were 
also seen in P21 mice with a further increase in the number of YFP+ cells expressing 
Glut2 and Pdx1 in the pancreata of the GKO;Rosa-YFP mice (Fig. 2.6H, J, L, Fig. S3). 
As expected, due to the leakiness of the Glucagon-Cre transgene, we did find a small, but 
not significant, percentage of YFP+ cells that coexpressed Glut2, MafA, or Pdx1 in P5 or 
P21 control;Rosa-YFP mice (Fig. 2.6A, C, E, G, I, K). Taken together, these data 
demonstrate that a subset of the converted cells in the GKO;Rosa-YFP mice activate β-
cell markers as well as insulin expression in the absence of Arx.
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Figure 2.6: YFP+ cells in GKO animals express markers of mature β-cells at P5 and 
P21. 
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Figure 2.6: YFP+ cells in GKO animals express markers of mature β-cells at P5 and 
P21.  (A-F): Control;Rosa-YFP and GKO;Rosa-YFP P5 pancreata were stained for  
insulin (blue), YFP (green), Glut2 (A,B,red), MafA (C,D,red), Pdx1 (E,F,brown). YFP+ 
cells in GKO animals are insulin+Glut2+ (B;  ), insulin+MafA+ (D; ) and insulin+Pdx1+ 
(F; ).  In control animals, the majority of YFP+ do not express β-cell markers (A,C,E).  
The YFP+ cells seen in exocrine tissue (panels E and F) is background due to the 
combined IHC, IF staining method used and not true signal. (G-L): Quantification of 
percentage of YFP+ cells that express or do not express Glut2 at P5 (G) and P21 (H), 
MafA at P5 (I) and P21 (J), and Pdx1 at P5 (K) and P21 (L). Over 200 YFP+ cells were 
counted for each stage with 3-5 animals per group. Error bars represent standard error of 
the mean with significance between each cell population (p≤0.05) denoted as “*” and 
“

”.  Male and female GKO mice (n≥3) were used for all analysis and compared to their 
sex-matched controls. Scale bar represents 25µm. 
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Short-term ablation of Arx in adult α-cells does not lead to loss of α-cell identity.  
 To explore the requirement for Arx in the maintenance of adult α-cell fate, we 
used a global, tamoxifen-inducible transgenic mouse model to ablate Arx in adult 
animals. Two-month-old control and ArxL/Y;pCAGG-CreER (IKO) mice were injected 
with tamoxifen for three consecutive days and the animals sacrificed two weeks later for 
tissue analysis (Fig. 2.7A). Efficiency of Arx removal was evaluated by immunostaining 
in control and IKO mice. While Arx expression was found in glucagon+ cells in control 
animals, all glucagon cells in IKO animals have lost Arx expression (Fig. 2.7B, B’, C, C’; 
marked by arrows). To determine the impact of short-term Arx ablation in adult α-cells, 
gene expression and immunostaining for endocrine hormones were examined in control 
and IKO animals (Fig. 2.7D-I). Real-time PCR analysis revealed no significant changes 
in the mRNA levels of hormone genes between control and IKO islets (Fig. 2.7K).  We 
also did not detect any significant changes in the numbers of glucagon-, insulin-, 
somatostatin-, and PP-producing cells in the IKO mice compared to controls (Fig. 2.7D-
J). Unlike P5 GKO mice in which a large proportion of Arx-glucagon+insulin+ cells were 
found (Fig. 2.7A-B), we detected only a small number of bihormonal cells in adult IKO 
mice, which were not proportionally significant (less than 0.1%; data not shown). 
Additionally, analysis of α- and β-cell factors including MafB, Brn4, Glut2, and Pdx1 
also did not reveal any significant changes in transcriptional profile of IKO animals (Fig. 
2.7L).  Since the pCAGG-Cre is globally expressed, the IKO animals develop an 
intestinal phenotype that excludes any meaningful analysis to explore the long-term 
impact of Arx on adult α-cell (data not shown).  Taken together, using our current mouse 
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model with short-term Arx ablation, these findings demonstrate that Arx is likely 
dispensable in maintaining α-cell identity in adult mice.  Future experiments utilizing an 
inducible α-cell specific Cre transgenic mouse will be required to study the long-term 
requirement for Arx in the maintenance of α-cell fate.   
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Figure 2.7: Short-term complete ablation of Arx in adult mice does not result in a 
loss of α-cells or changes in endocrine cell populations. 
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Figure 2.7: Short-term complete ablation of Arx in adult mice does not result in a 
loss of α-cells or changes in endocrine cell populations. (A): Diagram outlining 
experimental design. (B-C): Arx (red) is expressed in glucagon (green) cells in control 
(B,B’; arrows) but lost in IKO (C,C’;arrows) animals.  Asterisks (*) mark autoflourescent 
blood cells and are non-specific staining. (D-I): Control and IKO pancreata were stained 
for glucagon (green), insulin (red; D,E), somatostatin (Sst; red; F,G), and PP (red; H,I).  
No significant colocalization of glucagon with other hormones was seen in control or 
IKO mice. Male control and IKO mice were used for analysis though female control and 
IKO mice produced similar results. Scale bar denotes 75µm. 
 (J): Endocrine cell number quantification for insulin, glucagon, somatostatin, and PP in 
control and IKO animals (over 10,000 cells were counted from 3 animals per group). (K-
L): Quantitative PCR analysis of gene expression in control and IKO islets. Results are 
displayed as fold change relative to control with error bars representing the standard error 
of the mean. For all analysis n=3.  
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Discussion 
This study demonstrates a requirement of Arx in α-cell fate maintenance.  
Ablation of Arx in neonatal glucagon+ cells results in a loss of α-cell identity and 
conversion into an insulin-producing β-cell-like fate (Fig. 2.8).  Conversely, short-term 
ablation of Arx in adult animals did not result in a significant loss or conversion of α-cells 
or an increase in β-cells or β-cell markers (Fig. 2.8). Our findings from neonates and 
adults expand the previously defined role of Arx in the specification of α-cells.  When 
taken together, Arx plays a role during specification as well as during early maintenance 
of α-cell fate, but appears not to be required in adult animals for its fate maintenance. 
Others have shown that ablation of Arx at any stage of specification results in a 
complete loss of the α-cell lineage with a concomitant increase of β- and δ-cells 
[9,10,12,23]. As there is no change in total endocrine mass reported in these studies, 
these α-cells likely undergo re-specification into β- and δ-cell lineages.  Our findings add 
significant support to these observations by using lineage tracing to directly demonstrate 
that Arx-ablated α-cells convert to β-like cells in neonatal animals.  Interestingly, our 
data, while showing coexpression of glucagon and insulin, does not show coexpression of 
glucagon and somatostatin.  Our initial hypothesis was that Arx-deficient α-cells would 
give rise to both somatostatin and insulin populations.  It is possible that the inefficiency 
of the Glucagon-Cre did not enable us to detect a rare population of 
glucagon+somatostatin+ cells. Alternatively, as the animal ages, the plasticity of cells 
among different endocrine fates could be altered.   
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Previous studies have demonstrated that endocrine cell fate is relatively 
undifferentiated during gestation such that ablation of single transcription factors results 
in loss of cell fate [2].  As endocrine cells mature, however, this plasticity drastically 
decreases, and more extreme measures are needed to convert one endocrine cell type to 
another [4,6,8].  While Pdx1 is normally restricted to β-cells, early overexpression in α-
cells results in a postnatal loss of glucagon-expressing α-cells with a concomitant gain of 
insulin-producing β-cells demonstrating an α-to-β-cell fate conversion [8]. Conversely, 
overexpression of Pdx1 in adult α-cells does not result in a similar conversion; instead, 
these cells maintain proper cell identity [8].  The potential temporal requirement of Arx 
closely parallels the results obtained through Pdx1 overexpression in α-cells. Early in 
development, endocrine cell fate appears more plastic and subject to reprogramming.   
During later life, however, cell fate is more defined, and as a result, reprogramming is 
more difficult to achieve. 
Interestingly, although overexpression of Pdx1 in α-cells results in a gain of 
insulin-producing cells, those cells did not appear to lose all markers of α-cell fate [8]. 
Examination of immunostaining for the expression of β-cell-specific factors in the Arx 
ablated neonatal animals demonstrates that YFP+ cells are at least partially reprogrammed 
with the expression of Glut2, MafA, and Pdx1.  While Arx is necessary to maintain α-cell 
fate during development, loss of Arx, even immediately after specification, may not be 
sufficient to fully reprogram cells into a functional β-cell fate. Due to the low efficiency 
of the Cre utilized in our study, functional analysis of the insulin-producing cells derived 
from Arx ablation in α-cells was not feasible.   
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As the animal ages, there could be epigenetic changes that have occurred during 
the process of specification or maturation that inhibit these Arx deficient cells from 
becoming functional β-cells under homeostatic conditions.  In fact, epigenetic 
modification has been shown to play important roles in the differentiation and 
maintenance of cell types.  A recent study demonstrates that α-to-β-cell reprogramming 
could be promoted by manipulating the histone methylation signature in mammalian 
pancreatic islets [24]. Conditions of stress, however, may also make cell fate transitions 
more fluid.  It has been shown that excessive loss of β-cell mass, induced by 
administration of a β-cell specific toxin, results in spontaneous reprogramming of α-cells 
into a β-cell fate [6].  Additionally, partial pancreatectomy in mice and rats can result in 
regeneration of β-cells through the conversion of duct cells or duct progenitor cells 
[25,26].  These studies demonstrate that while cell fate is more defined in adult animals, 
extreme conditions can force a non-β-cell into a β-cell fate. Future studies examining this 
possibility should be performed and will elucidate limits to cell fate maintenance in adult 
animals and how to overcome those limits.  Particularly, the ability to utilize α-cells for 
conversion to functional β-cells could be a potential therapy for diabetes. 
Finally, it is important to note that our current adult IKO mouse model does not 
allow for a complete investigation for the role of Arx in adult α-cells.  Arx is required in 
early enteroendocrine cell development of the digestive tract [27].  Therefore mice with 
Arx removal in the intestine have alterations of specific enteroendocrine cell population, 
which lead to lipid malabsorption and diarrhea ([27]; and unpublished observations). 
Since the adult IKO mouse model was generated using a global inducible Cre transgenic 
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mouse, enteroendocrine cell populations were impacted (unpublished observations).  It is 
important to note that we did notice a 0.1% increase in the number of bihormonal cells in 
IKO mice (data not shown). However, whether this small change is due to the direct 
impact upon Arx loss in α-cells or changes in the animal’s physiology remains to be 
determined. An α-cell specific inducible Arx-deficient mouse model combined with 
lineage tracing studies will be required to precisely determine the role of Arx in adult α-
cells. 
In conclusion, the current study demonstrates a potential temporal requirement for 
Arx in maintenance of α-cell fate.  Ablation of Arx in neonatal α-cells results in a loss of 
glucagon expression and a conversion of this cell population to adopt an insulin-
producing β-cell-like fate.  However, short-term loss of Arx in adult animals does not 
phenocopy this result but instead suggests that Arx is dispensable in maintaining α-cell 
fate in adulthood.  These data expand the knowledge of the field not only related to the 
role of Arx in the endocrine α-cell but also in regards to global temporal restrictions for 
reprogramming endocrine cells.  Future studies examining this temporal requirement, as 
well as perturbations to the cell that circumvent these restrictions, will help clarify this 
plasticity and bring understanding to endocrine cell fate specification, maintenance, and 
therapeutic potential. 
Note: The data presented in this chapter has been published in PLOS ONE as an Original 
Research Article entitled, 
Pancreatic α-cell specific deletion of mouse Arx leads to α-cell identity loss. 
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Figure 2.8: Proposed model showing that Arx is necessary to maintain α-cell fate in 
neonatal islets but not in mature α-cells in adult animals. 
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Figure 2.8: Proposed model showing that Arx is necessary to maintain α-cell fate in 
neonatal islets but not in mature α-cells in adult animals. Loss of neonatal Arx results 
in the conversion of glucagon+ α-cells into an insulin-producing β-like-cell through a 
bihormonal intermediate.   
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Materials and Methods 
Ethics Statement 
The Children’s Hospital of Philadelphia’s Institutional Animal Care and Use Committee 
(IACUC) approved all animal experiments under the protocol number 2011-10-756. 
CLM monitored all animal studies. 
Animals and Breeding Strategy  
The derivation of the ArxL/Y and Glucagon-Cre transgenic lines has previously been 
described [14,15,16].  To generate ArxL/Y;Glucagon-Cre mice, ArxL/+;Glucagon-Cre and 
ArxL/Y mice were mated on a BL6 background. Male and female ArxL/Y or 
ArxL/L;Glucagon-Cre mice were phenotypically indistinguishable in terms of their islet 
morphology, size, body size and weight. All mutants used in our analysis were compared 
to their sex-matched controls. Arx+/Y;Glucagon-Cre, Arx+/Y, ArxL/+ and ArxL/+;Glucagon-
Cre mice were used for controls with no observable phenotypic differences in the islets 
between any of them. The reporter Rosa26YFP/YFP was mated into this line in either 
heterozygosity or homozygosity for lineage tracing studies, which yielded the same result 
in all experiments [17]. The generation of pCAGG-CreER animals has been previously 
described [18].  ArxL/Y or ArxL/L;pCAGG-CreER animals were generated by crossing 
ArxL/+;pCAGG-CreER females to ArxL/Y males. Male and female mutants were 
phenotypically indistinguishable in the endocrine pancreas and both were used in this 
study.  
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Immunohistochemistry and Histology 
All dissections were performed in cold 1X PBS and tail or toe snips collected for 
genotyping.  Tissues were fixed in cold 4% paraformaldehyde overnight at 4°C, 
embedded in paraffin, and 8µm sections collected.  Antigen retrieval was performed in 
10mmol citric acid buffer (pH 6.0) and endogenous peroxidase, avidin D, and biotin 
activity blocked with 3% H2O2 (Sigma) and Avidin/Biotin Blocking Kit (Vector), 
respectively.  Endogenous protein was blocked with CAS-Block reagent (Invitrogen). 
Slides were incubated in primary antibody overnight at 4°C.  Primary antibodies used 
were: Insulin (MS 1:400, Thermo Scientific and GP 1:1000, Abcam), Glucagon (1:3000, 
Millipore), Somatostatin (1:200, Invitrogen), PP (1:200, Invitrogen), Arx (1:250, gift 
from Dr. Kanako Miyabayashi at Kyushu University), GFP (1:250, Abcam), Ghrelin 
(1:200, Santa Cruz), Pdx1 (1:200, Santa Cruz), MafA  (1:1000, Bethyl), Glut2 (1:1000, 
Millipore), and Chromogranin A (1:3000, DiaSornin). After rinsing in PBS, appropriate 
secondary antibodies were added for two hours at room temperature. 
Immunohistochemical detection was performed with the VECTASTAIN ABC kit 
(Vector Laboratories) and diaminobenzidine tetrahydrochloride (DAB) as the substrate.  
Immunofluorescence utilized secondary antibodies conjugated to Cy3, Cy2 or Cy5. All 
images were obtained using a Leica DM6000B microscope. 
Real-Time PCR Analysis 
Total RNA was extracted in TRIZOL (Invitrogen) using the protocol provided with 
reagent.  Oligo-dT, Superscript II, and additional required reagents were used to 
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synthesize cDNA (Invitrogen).  PCR reactions were performed using Brilliant SYBR 
Green PCR Master Mix (Agilent) in the Stratagene Mx3005P real-time PCR machine.  
All PCR reactions were performed in duplicate for each sample with at least 3 animals 
per group analyzed with reference dye normalization. Primer sequences are available 
upon request. 
Hormone Cell Quantification 
Hormone-positive cells from pancreatic sections were counted, averaged, and normalized 
to either total pancreatic area or total endocrine cell number.  Three separate regions of 
each pancreas were used for quantification in both control and mutant mice. At least three 
animals for each group were used for quantification in all analyses.  To determine 
hormone cell mass, hormone-positive area as well as pancreatic area was measured using 
the Aperio Image Analysis System.  These areas as well as weight of the pancreas was 
used to determine hormone cell mass.  For specific hormone cell number, hormone 
positive cells were counted and normalized to total endocrine cell number, which was 
determined by combining counts for all endocrine hormones (insulin, glucagon, 
somatostatin, and PP). Over 10,000 total endocrine cells were counted for each analysis 
consisting of over 5,000 insulin+, over 1,000 glucagon+ and somatostatin+, and over 500 
PP+ cells.  
Islet Isolation 
For P21 and adult RNA analysis, islet isolation was performed by injecting 5 mL 
Collagenase P (Roche) in HBSS with 0.02% BSA (Sigma) into the clamped pancreatic 
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duct to inflate the pancreas.  Once inflated and removed, pancreatic tissue was incubated 
in 15mL CollagenaseP/HBSS at 37°C at 50rpm for 16 minutes to digest exocrine tissue.  
After spin down and rinse, islets were isolated from remaining exocrine tissue in HBSS.  
Upon isolation, islets were placed in TRIZOL for RNA extraction. 
Tamoxifen Induction 
Two-month-old male and female mice, matched with littermate controls, were injected 
intraperitoneally (IP) with 50µg/g body weight of 10mg/ml tamoxifen (Sigma) solution, 
which consisted of 10% ethanol and 90% sunflower seed oil (Sigma).  Injections were 
performed for three consecutive days followed by a two-week chase.  After the chase 
period, pancreatic tissue was removed and processed for either immunostaining or RNA 
analysis. 
Statistical Analysis 
All values are presented as average ± standard error of the mean.  Significance was 
determined using a two-tailed Student’s t-test. p-values less than or equal to 0.05 were 
considered significant.   
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Chapter III: 
 
The Role of Arx in Maintenance of Adult α-cell Fate 
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Abstract 
 Type II diabetes is a global health crisis, affecting more than 25 million people in 
the United States alone.  Diabetes is a metabolic disorder that stems from unregulated 
glucose homeostasis, which is normally maintained by glucagon-producing α-cells and 
insulin-producing β-cells in the endocrine pancreas.  In order to develop novel treatments 
for type II diabetes, knowledge of normal endocrine cell development and maintenance is 
essential.  Previous studies have demonstrated the importance of transcription factors in 
endocrine cell development.   
An important transcription factor for endocrine α-cells is the aristaless-related 
homeobox gene (Arx).  Previous studies have demonstrated that Arx is necessary for 
proper specification and maintenance of α-cell fate in the neonatal pancreas, but is 
dispensable for short-term α-cell fate maintenance in adult animals.  However, the long-
term impact of Arx ablation in mature α-cells has not been studied.   
Here, we show that upon long-term ablation of Arx in mature α-cells, mice 
become more glucose tolerant and lose weight gradually over time.  Phenotypic analysis 
demonstrated normal glucagon+ numbers; however, a majority of α-cells co-express 
insulin or PP.  Finally, in vitro secretion assays demonstrate loss of glucagon secretion 
and content.  Instead, Arx-ablated islets secrete insulin in response to both α and β 
stimuli.  When taken together, these data demonstrate that long-term ablation of Arx in 
the mature α-cell results in loss of cell fate maintenance and conversion into an α-β-PP 
hybrid cell. 
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Introduction: 
 
 Type II diabetes is a metabolic disorder that affects over 25 million people in the 
United States [1].  The hallmarks of type II diabetes are inadequate insulin secretion 
combined with excess glucagon due to loss of proper glucose homeostasis [2].  Glucose 
homeostasis is largely maintained by the endocrine pancreas, which secretes insulin and 
glucagon in response to elevated and reduced blood glucose levels, respectively [3].  
Thus, novel therapies to treat type II diabetes focus on the endocrine pancreas and seek to 
restore blood glucose homeostasis [4]. 
 The pancreas is a two-component organ situated between the stomach and 
duodenum of the digestive tract [5].  The pancreas is comprised of an exocrine portion, 
which secretes digestive enzymes, and an endocrine component, which produces and 
secretes hormones involved in glucose homeostasis and metabolism [5].  The murine 
endocrine portion of the pancreas is organized into Islets of Langerhans, consisting of a 
core of insulin-producing β-cells with a surrounding mantle of α-, δ-, PP-, and ε-cells, 
which secrete the hormones glucagon, somatostatin, Pancreatic Polypeptide (PP), and 
ghrelin, respectively [5]. 
 Glucose homeostasis is maintained by insulin-producing β-cells and glucagon-
producing α-cells [3].  Increased blood glucose levels causes insulin secretion from β-
cells, uptake and storage of excess glucose in skeletal muscle and adipose tissue, and 
lowering of blood glucose concentration [3].  Conversely, when blood glucose levels fall 
below baseline, insulin secretion is halted and amino acids are released, signaling α-cells 
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to secrete glucagon [3]. Glucagon signals to the liver to break down stored glucose 
through the processes of gluconeogenesis and glycogenolysis, resulting in an increase in 
blood glucose concentration [6]. The opposing processes induced by glucagon and insulin 
act to maintain proper blood glucose homeostasis. 
 In order to develop novel therapies for type II diabetes, knowledge of normal 
pancreatic endocrine cell development and maintenance is critical.  Previous studies have 
demonstrated the crucial role transcription factors play in endocrine specification and 
maintenance [1].  During development, ablation of essential transcription factors leads to 
loss of cell fate specification and/or maintenance [1].  However, in adult animals 
pancreatic cell fate is more defined, and ablation of transcription factors is less likely to 
result in complete loss of cell fate [1].  Cell fate is maintained in mature endocrine cells 
through a combination of a complex transcriptional program and extensive chromatin 
modifications [7].   
 In endocrine α-cells, one such crucial transcription factor required for proper 
specification and maintenance is the homeodomain-containing protein aristaless-related 
homeobox gene (Arx) [8]. Ablation of Arx during development results in the complete 
loss of the α-cell lineage and reallocation of presumptive α-cells into β- and δ-cell fates 
[8,9].  Furthermore, forced misexpression of Arx in the developing pancreas or islets 
leads to conversion of β- and δ-cells into α- and PP-cell fates [10].  Thus, Arx is 
necessary and sufficient for α-cell specification. 
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 Arx is also necessary for neonatal α-cell fate maintenance [9].  Arx is exclusively 
expressed in glucagon+ α-cells at all time points examined after specification [8].  Loss of 
Arx in glucagon+ α-cells results in conversion of Arx-ablated α-cells into a β-like cell fate 
through an insulin+glucagon+ bihormonal intermediate [9].  However, short-term ablation 
of Arx in mature α-cells does not result in loss of α-cells or misexpression of other 
endocrine hormones [9].   
 This previous study characterized the role of Arx in maintenance of neonatal α-
cell fate and began to explore this role in mature α-cells [9]. Although short-term (2 
weeks) ablation of Arx in mature α-cells does not result in a visible phenotype, the long-
term (~8 weeks) impact of this ablation has not been explored.  Here, we demonstrate 
that long-term ablation of Arx in mature α-cells results in improved glucose tolerance, 
gradual weight loss, and misexpression of insulin and PP, but not somatostatin, in 
glucagon+ cells.  In vitro secretion studies of Arx-ablated islets demonstrate loss of 
glucagon secretion in response to incubation with a mixed amino acid solution and 
instead insulin is secreted in response to α- and β-cell stimuli.  Additionally, Arx-ablated 
islets display severely reduced glucagon content.  These results suggest that long-term 
ablation of Arx in adult α-cells leads to loss of proper cell fate maintenance and 
conversion of α-cells into an α-β-PP hybrid cell that no longer secretes glucagon, but 
instead produces and secretes insulin in response to both α- and β-cell stimuli. 
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Results: 
Ablation of Arx in adult animals leads to improved glucose tolerance 
 Short-term ablation (2 weeks) of Arx using a global, tamoxifen-inducible mouse 
model has been previously described [9].  To determine the long-term consequence 
associated with ablation of Arx in adult mice, the same mouse model was utilized.  Two-
month old control, ArxL/Y;pCAGG-CreER male, and ArxL/L;pCAGG-CreER female (IKO 
from here on) mice were induced with tamoxifen then analyzed by glucose tolerance tests 
(GTT) every two weeks to monitor changes in glucose homeostasis over time.   
 Two weeks post-induction, control and IKO mice demonstrated similar blood 
glucose levels after an overnight fast (Fig. 3.1A).  However, IKO mice had significantly 
lower fasting blood glucose levels four and six weeks post induction when compared to 
controls (Fig. 3.1B-C).  Interestingly at eight weeks post induction IKO mice no longer 
demonstrated significantly lower fasting blood glucose levels, though the data were 
approaching significance (Fig 3.1D).   
 Similar to the fasting blood glucose levels, IKO mice demonstrated a slightly, but 
not significantly, improved glucose tolerance starting at four weeks post induction (Fig. 
3.1B-D).  Two weeks post induction control and IKO mice demonstrated similar glucose 
tolerances (Fig. 3.1A).  While control and IKO mice peaked at relatively the same blood 
glucose level during GTT, IKO mice returned to baseline faster.    
 Starting at 6 weeks post-induction, IKO mice began to display diarrhea, weight 
loss, and eventually rectal discharge (data not shown).  On average, control mice gained 
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around 2g after induction (Fig 3.1E).  Conversely, IKO mice began to lose weight 
starting at six weeks and weighed significantly less than controls by eight weeks post 
induction.   
 However, Arx is also required for proper enteroendocrine cell specification [11]. 
The model utilized in this study is a global ablation model resulting in ablation of Arx in 
the pancreas as well as the intestine.  Thus, it is likely that the physiological data 
presented are due to ablation of Arx in the intestine as well as the pancreas.  However, 
when taken together, these data suggest that while short-term ablation of Arx does not 
result in a visible phenotype, long-term ablation of Arx results in improved glucose 
tolerance and weight loss.  To examine the pancreas specific defects associated with 
ablation of Arx in mature α-cells immunohistochemistry and in vitro assays were 
performed. 
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Figure 3.1: IKO animals display improved glucose tolerance and weight loss over 
time  
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Figure 3.1: IKO animals display improved glucose tolerance and weight loss over 
time (A-D): Glucose tolerance tests for control (black circles) and IKO mutant mice 
(white boxes) two(A), four(B), six(C), and eight(D) weeks after ablation of Arx.  Results 
are graphed as blood glucose levels measured at 0, 15, 30, 60, 90, and 120 minutes after 
injection of a bolus of glucose.  (E): Change in weight from initial induction to six and 
eight weeks post induction.  Results are graphed as change in weight with controls 
represented by the black bars and IKO mutants represented with the white bars.  All 
results are presented as ±SEM with (*) denoting significance where p<0.05.  Non-
significant data p values are indicated on corresponding charts. Five control and five IKO 
mice were utilized for each experiment.  
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IKO glucagon+ α-cells misexpress insulin and PP, but not somatostatin, eight weeks 
after ablation of Arx  
 Previous studies have demonstrated that short-term ablation of Arx does not result 
in loss of α-cells or significant misexpression of other endocrine hormones even with 
complete loss of Arx expression [9].  To determine if a long-term ablation of Arx results 
in a pancreatic phenotype, control and IKO pancreata were examined nine weeks post 
induction for the presence, localization, and segregation of glucagon, insulin, 
somatostatin, and PP.  Similar to the previous study, no apparent change in the quantity 
or localization of glucagon+ cells was noted in IKO mice (Fig 3.2).  However, in contrast 
to short-term ablation of Arx, long-term ablation resulted in the misexpression of insulin 
and PP in glucagon+ cells (Fig 3.2 A, B, E, F).  No co-expression was noted in control 
animals.  Approximately 50% of glucagon+
 
cells in IKO animals co-expressed the 
endocrine hormone insulin. Furthermore, a few α-cells were also noted to co-express PP 
and glucagon.  Conversely, no misexpression of somatostatin was noted in control or 
IKO pancreata (Fig 3.2C-D).  These data demonstrate that long-term ablation of Arx in 
adult animals does not result in loss of glucagon+ α-cells, but does result in misexpression 
of the endocrine hormones insulin and PP in a subset of α-cells in IKO mice.  
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Figure 3.2: 9 weeks after ablation of Arx, glucagon+ cells coexpress the endocrine 
hormones insulin and PP, but not somatostatin 
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Figure 3.2: 9 weeks after ablation of Arx glucagon+ cells coexpress the endocrine 
hormones insulin and PP, but not somatostatin. (A-F): Control (left) and IKO (right) 
pancreatic sections were stained for glucagon (green) and insulin (red, A-B), somatostatin 
(red, Sst, C-D), and PP (red, E-F).  No change in the number of glucagon+ cells was 
apparent in IKO animals.  However, many glucagon+ cells coexpressed the endocrine 
hormones insulin and PP, but not somatostatin.  Images are representative from five 
controls and five IKO animals utilized for each experiment. (*) represent autoflourescing 
blood cells not real signal. Arrows point to copositive cells.  Enlarged image in upper left 
hand corner represents boxed in cells in corresponding image. 
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IKO islets display loss of glucagon secretion and improper insulin secretion in 
response to α-cell stimuli 
 Given the striking bihormonal phenotype in α-cells upon Arx ablation in the adult 
pancreas, it was crucial to determine if these mutant islets still properly secrete hormones 
in response to glucose and amino acid stimulation.  Further, since IKO animals 
demonstrate diarrhea and weight loss from an intestinal phenotype, we utilized in vitro 
secretion assays to isolate islet function from that of the intestinal phenotype.  Control 
and IKO islets were incubated with either media (no stimulation), a 4mM mixed amino 
acid solution (stimulates glucagon secretion), or a 10mM glucose solution (stimulates 
insulin secretion).  After stimulation, insulin or glucagon secretion was measured.   
 Glucagon secretion in vitro assays demonstrated that control islets secreted 
glucagon upon stimulation with a mixed amino acid solution, but not a glucose solution 
(Fig. 3.3A).  However, IKO islets had a lower basal level of glucagon secretion and failed 
to secrete glucagon in response to a mixed amino acid solution (Fig 3.3A).  This finding 
demonstrates loss of glucagon secretion upon long-term ablation of Arx.  
 To further characterize the secretion properties of IKO islets insulin secretion in 
vitro assays were performed.  Control islets released insulin in response to a 10mM 
glucose solution, but not a mixed amino acid solution (Fig 3.3B).  Conversely, IKO islets 
released insulin when stimulated with both a 10mM glucose and 4mM amino acid 
solution (Fig 3.3B).  This result demonstrates that long-term ablation of Arx results in 
improper insulin secretion in IKO islets. 
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 Finally, insulin and glucagon content was measured in control and IKO isolated 
islets.  While insulin content was similar between control and IKO islets, glucagon 
content was drastically reduced in IKO islets when compared to controls (Fig. 3.3C-D).  
When taken together, these data demonstrate loss of glucagon content and secretion upon 
long-term Arx ablation in adult pancreata.  Instead, Arx-ablated α-cells secrete insulin in 
response to both α- and β-cell stimuli. 
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Figure 3.3: IKO islets have reduced glucagon secretion and content with improper 
insulin secretion  
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Figure 3.3: IKO islets have reduced glucagon secretion and content with improper 
insulin secretion. (A-B): In vitro insulin (A) and glucagon (B) secretion assay for control 
(black bars) and IKO (white bars) islets in response to media (G0, no stimulation), a 4.0 
mM mixed amino acid solution (AAM, glucagon secretion), and a 10mM glucose 
solution (G, insulin secretion).  Results are graphed as ng of insulin or pg of glucagon 
secreted per 50 islets in 30 minutes.  (C-D): Insulin (C) and glucagon (D) content in 
control (black bar) and IKO (white bar) islets.  Results are graphed as ng of insulin/pg of 
glucagon per islet.  All results are graphed as ± SEM with (*) denoting significance 
where p≤0.05. n.s. indicates results that are not significant.  Above studies were 
performed by Dr. ChangHong Li 
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Discussion: 
 The data presented here demonstrate loss of proper α-cell fate maintenance upon 
long-term ablation of Arx in adult mice.  Eight weeks after tamoxifen induction, IKO 
mice demonstrate improved glucose tolerance, misexpression of insulin and PP, loss of 
glucagon secretion and content, and gain of insulin secretion in response to α-cell stimuli.  
These data suggest that ablation of Arx results in loss of α-cell fate and conversion of 
these cells into an α-β-PP hybrid cell that expresses multiple hormones, but exclusively 
secretes insulin in response to both α- and β-cell stimuli.  Overall, these results expand 
the previously defined role for Arx, and demonstrate that Arx is necessary for cell fate 
maintenance in mature α-cells. 
 
An α-cell specific ablation of Arx is essential to determine pancreas specific 
physiological defects. 
 The data presented here were obtained using a global, tamoxifen-inducible 
transgenic mouse model, resulting in ablation of Arx in the entire animal upon 
administration of tamoxifen.  Prior studies have demonstrated that Arx is necessary for 
the proper development and maintenance of several different tissues, including the brain, 
digestive tract, testis, muscle, and pancreas [8,11,12,13,14].  Thus, the physiological 
defects described here, such as improved glucose tolerance, weight loss, and diarrhea, 
cannot be attributed solely to loss of Arx in the pancreas.  Rather, it is likely that these 
observed phenotypes are due to the ablation of Arx in multiple tissue types, especially the 
  
101 
digestive tract.  However, the immunohistochemistry and in vitro secretion assays 
performed demonstrate a clear pancreas specific defect separate from that of the intestine.  
These studies allowed pancreas specific analysis of the phenotype and demonstrate that 
long-term ablation of Arx in mature α-cells results in loss of cell fate maintenance.  
Future studies utilizing an α-cell specific model will clarify the physiological, pancreas 
specific, defects, as well as uncover other less severe phenotypes not observed in this 
global study. 
 
Long-term ablation of Arx in mature α-cells results in loss of cell fate maintenance. 
 We first demonstrated that short-term (2 weeks) ablation of Arx in adult mice 
does not result in loss of α-cells or misexpression of other endocrine hormones [9].  We 
demonstrate that, using the same model, eight weeks post induction the majority of α-
cells express multiple hormones, have lost glucagon secretion and content, and 
improperly secrete insulin in response to α-cell stimuli.  These data demonstrate that Arx 
is necessary for long-term α-cell fate maintenance and function in mature α-cells.  
 While no apparent defects were noted 2 weeks post induction, Arx-deficient α-
cells were likely beginning to lose control of cell fate maintenance.  However, there are 
other cellular mechanisms in place to help maintain α-cell fate.  Previous studies have 
demonstrated that mature α-cells have a vast landscape of activating and repressing 
chromatin marks [15].  This landscape aids in maintaining the proper transcriptional 
program in addition to expression of the correct transcription factors and proteins [15].  A 
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situation can be imagined where, upon ablation of Arx, other transcription factors and the 
remaining chromatin structure are able to maintain α-cell fate for a brief period of time.  
However, in the long term, these chromatin marks begin to erode and the necessary 
transcriptional programs begin to slip, resulting in loss of α-cell fate, misexpression of 
other endocrine hormones, and subsequent loss of correct signaling mechanisms.  Future 
studies examining the role of histone modifications in mature α-cells, as well as a more 
detailed description of α-cell characteristics following ablation of Arx, will clarify this 
result, explore the above hypothesis, and begin to address how cell fate is maintained 
short-term and long-term in the mature endocrine pancreas. 
 
Arx-ablated α-cells respond to both α- and β-cell stimuli by secretion of insulin. 
 In vitro stimulation of endocrine islets with glucose and amino acids is an 
accurate and sensitive way to examine insulin and glucagon secretion, respectively [16].  
Control islets responded correctly to each stimulus, secreting insulin in response to a 
glucose solution and glucagon in response to a mixed amino acid solution.  However, 
IKO islets improperly responded to both stimuli, failing to secrete glucagon in response 
to amino acids and instead secreting insulin in response to both glucose and amino acids.   
 This result indicates that upon ablation of Arx, α-cells begin to resemble an α-β-
PP hybrid cell that is able to respond via insulin secretion to both α- and β-cell stimuli. 
Although ablation of Arx leads to loss of α-cell fate maintenance and glucagon secretion, 
it does not result in loss of glucagon+ α-cells as seen upon neonatal ablation [9].  Future 
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studies examining a longer chase period after ablation of Arx will be useful in 
determining if these hybrid cells eventually lose glucagon expression and acquire a pure 
β-cell phenotype.  Alternatively, these cells could remain trapped in an intermediate fate 
and continue to secrete insulin in response to both α- and β-cell stimuli. 
 Additionally, these data will be useful in developing novel treatments for type II 
diabetes.  Because type II diabetes results from inadequate insulin supply combined with 
excess glucagon secretion, therapies utilizing endogenous α-cells and transdifferentiating 
them into functional β-cells would present an ideal therapy [2,4].  If Arx-ablated α-cells 
eventually differentiate into a pure β-cell fate, this result can then be expanded as a 
possible novel treatment for diabetic patients.   
 
Conclusion 
 The data presented here demonstrate an essential role for Arx in the maintenance 
of mature α-cell fate.  Long-term ablation of Arx in adult animals leads to loss of α-cell 
fate maintenance.  IKO mice display an improved glucose tolerance over time as well as 
diarrhea and weight loss.  Phenotypic analysis determined co-expression of insulin and 
PP in glucagon+ cells.  In vitro secretion assays showed loss of glucagon secretion.  
However, the IKO islets were able to secrete insulin in response to amino acids which 
normally only stimulates glucagon secretion.  These results demonstrate that Arx is 
necessary for α-cell fate maintenance.  Future α- to β-cell transdifferentiation therapies 
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for type II diabetes focused on the role of Arx in α-cell fate may provide an avenue for 
endogenous restoration of normal blood glucose homeostasis. 
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Materials and Methods: 
Animals and Breeding Strategy 
 The derivation of the Arx floxed and pCAGG-CreER transgenic lines has been 
previously described [17,18].  IKO mice were generated by crossing heterozygous 
ArxL/+;pCAGG-CreER females to ArxL/Y males.  IKO mutant mice consisted of 
ArxL/Y;pCAGG-CreER males and ArxL/L;pCAGG-CreER females.  Control mice 
consisted of littermate sex-matched animals, both male and female, including Arx+/Y, 
Arx+/Y;pCAGG-CreER, ArxL/Y, ArxL/+, ArxL/+;pCAGG-CreER, and ArxL/L.  No 
significant differences were noted between any control animals in terms of pancreatic and 
islet size, weight, or morphology.  Male and female IKO animals were phenotypically 
identical and used interchangeably in this study. 
 
Immunohistochemistry 
 Dissections were performed in cold 1X PBS.  The entire pancreatic tissue was 
removed, weighed, and submerged in cold 4% PFA/PBS overnight at 4°C.  Tissue was 
then rinsed, dehydrated, embedded in paraffin, and sectioned at 8 µm on charged glass 
slides.  Immunohistochemistry was performed using 10 mmol citric acid buffer (ph 6.0) 
for antigen retrieval followed by blocking endogenous protein using CAS-Block reagent 
(Invitrogen). Primary antibodies were added and slides incubated overnight at 4°C.  
Primary antibodies used were: Insulin (MS 1:400, Thermo Scientific and GP 1:1000, 
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Abcam), Glucagon (GP 1:3000, Millipore and Rb 1:1000, Chemicon), Somatostatin (Rb 
1:200, Invitrogen), and PP (Rb 1:200, Invitrogen) 
 
Tamoxifen Induction 
Two-month old IKO and matched littermate controls were injected with 50 µg/g 
body weight of 10 mg/ml tamoxifen solution to induce Cre expression.  Tamoxifen was 
dissolved in a solution of 10% ethanol and 90% sunflower seed oil (Sigma).  IKO and 
control animals consisted of both male and female mice.  Injections were intraperitoneal 
and performed on three consecutive days followed by a specified chase period (2-8 weeks 
post induction).   
Alternatively, induction was accomplished using an oral gavage system with the 
same concentration of tamoxifen solution and induction strategy previously described.  
Both methods resulted in similar ablation with no significant differences observed.  
 
Glucose Tolerance Test 
 Glucose homeostasis was examined using an intraperitoneal glucose tolerance 
test.  Mice were fasted overnight and injected with a bolus of glucose (2g/kg body 
weight, Sigma).  Blood glucose levels were measured at 0, 15, 30, 60, 90, and 120 
minutes post injection using an automatic glucometer (One Touch Ultra; LifeScan).   
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Islet Isolation and Culture 
 Control and IKO islets were isolated via collagenase digestion.  Once isolated 
islets were cultured in 10mM glucose RMPI 1640 media (Sigma) for three to four days.  
Culture media consisted of 2mM glutamine, 100units/ml penicillin, and 50µg/ml 
streptomycin.  Islets were maintained at 37°C.  Islet Isolation studies were performed by 
Dr. ChangHong Li of the Children's Hospital of Philadelphia. 
 
In vitro Secretion Assays 
 50 islets from each control and IKO animal were placed in 96-well plate, pre-
incubated in warmed KRBB (115mM NaCl, 24mM NaHCO3, 5mM KCl, 1mM MgCl2, 
2.5mM CaCl2, pH 7.4) buffer for 30 minutes at 37°C, and than stimulated with either a 
4.0mM mixed amino acid solution or a 10mM glucose solution for 30 minutes at 37°C. 
Supernatant was removed from well and glucagon secretion measured (Cisbio glucagon 
kit) or diluted 10X and insulin secretion measured (Cisbio insulin kit). Molecular Devices 
M5e plate reader was utilized to measure glucagon and insulin. 
 
Insulin and Glucagon Content 
 Islets were isolated and washed 2X in cold 1X PBS in 96-well plate.  100µl 
homogenization buffer (10mM Trisma, 10mM Sodium Acetate, 10µM EDTA, 1% Triton 
X-100, pH 7.4) was added, islets were homogenized, and diluted 100X for glucagon 
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content or 2000X for insulin content.  Molecular Devices M5e plate reader was utilized 
to measure insulin and glucagon content.  
 
Statistical Analysis 
 All results are graphed as ± the standard error of the mean (SEM).  In all 
calculations significance was determined using a two-tailed Student’s t-test where p≤0.05 
was considered significant.  Other p values that did not reach significance, but were 
deemed meaningful are displayed on the corresponding graphs/charts. 
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CHAPTER IV: 
 
Arx polyalanine expansion in mice leads to reduced pancreatic α-cell 
specification and increased α-cell death 
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Abstract  
 ARX/Arx is a homeodomain containing transcription factor necessary for the 
specification and early maintenance of pancreatic endocrine α-cells. Many transcription 
factors important to pancreas development, including ARX/Arx, are also crucial for proper 
brain development.  Although null mutations of ARX in human patients result in the 
severe neurologic syndrome XLAG (X-linked lissencephaly associated with abnormal 
genitalia), the most common mutation is the expansion of the first polyalanine tract of 
ARX, which results primarily in the clinical syndrome ISSX (infantile spasms).  
Subsequent mouse models of XLAG, ISSX and other human ARX mutations demonstrate 
a direct genotype-phenotype correlation in ARX-related neurologic disorders. 
Furthermore, mouse models utilizing a polyalanine tract expansion mutation have 
illustrated critical developmental differences between null mutations and expansion 
mutations in the brain, revealing context-specific defects.  Although Arx is known to be 
required for the specification and early maintenance of pancreatic endocrine α-cell, the 
consequence of a polyalanine expansion has not been explored.   
We report here that mice with an expansion mutation in the first polyalanine tract 
of Arx have impaired α-cell specification and maintenance with apoptosis playing a 
critical role in gradual α-cell loss.  This finding is novel and distinct from what was 
reported in mice with germ-line Arx null mutation, in which α-cells were re-specified into 
β- and δ-cells.  Overall, this analysis of an Arx polyalanine expansion mutation on 
pancreatic development further defines the critical nature of timing in α-cell specification 
and maintenance. 
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Introduction 
Aristaless-related homeobox gene (Arx) encodes a homedomain containing 
transcription factor that is expressed in the brain, testis, muscle, pancreas, and digestive 
tract [1,2].  In the brain, Arx is essential for the proper development and migration of 
GABA-ergic interneurons and has a role in cortical ventricular zone proliferation [3,4].  
In humans, various mutations of ARX result in a spectrum of neurologic disorders, the 
most severe clinical presentation being  X-linked lissencephaly associated with abnormal 
genitalia (XLAG) [5].  XLAG, which has been linked to null and missense mutations in 
ARX, is characterized by a severe brain malformation, termed lissencephaly, corpus 
callosum agenesis, neonatal-onset intractable epilepsy, and early death [6]. Arx null mice 
phenocopy the clinical presentation of XLAG patients, displaying cortical brain 
malformations and agenesis with lethality within 24-hours of birth [3,4].  Histological 
and molecular analyses reveal a dual function for Arx in radial and tangential migration 
of GABA-ergic interneurons in mice [7].  
Interestingly, polyalanine expansion mutations are the most common ARX 
mutations found in human disease [8]. ARX contains four polyalanine repeat tracts 
spaced throughout the protein [9].  It is the first two polyalanine repeats that are most 
often expanded in human disease [10]. Patients with these expansion mutations present 
with severe neurologic phenotypes, including seizures and mental retardation, but without 
brain malformations [11].  Expansion of the first polyalanine tract by an additional seven 
alanines has been associated with West Syndrome or infantile spasms (ISSX) [12].   
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Analyses using genetically modified mouse models have been performed to 
explore the impact different ARX polyalanine expansion mutations have on neuronal 
development and cognitive functionality; these models demonstrate a similar genotype-
phenotype correlation to humans [13]. Specifically, mouse models with an expansion 
mutation of the first polyalanine tract of Arx reveal that only tangential migration of 
GABA-ergic interneurons is lost, with no significant impact to radial migration [14,15]. 
Thus, it appears that expansion of the first polyalanine tract of Arx results in context 
specific defects in neural development. 
 In addition to the profound effects ARX/Arx mutations have on the brain, it also 
has a severe impact on the development of other organs.  Of note, Itoh and colleagues 
recently described complete loss of glucagon-producing α-cells in the pancreas of an 
ARX-null XLAG patient [16]. The mammalian pancreas contains an endocrine and 
exocrine compartment that functions to produce and secrete hormones and enzymes 
necessary for glucose homeostasis and digestion, respectively [17].  The endocrine 
compartment is organized into Islets of Langerhans with a core of insulin-producing β-
cells and a surrounding mantle of α-, δ-, ε-, and PP-cells producing the hormones 
glucagon, somatostatin, ghrelin, and pancreatic polypeptide, respectively [18]. Arx is 
expressed in Ngn3+ endocrine progenitors and then restricted to the α-cell lineage where 
it is expressed throughout the life of the animal [2].  Loss of glucagon-producing α-cells 
in XLAG patients suggests that ARX is necessary for specification and/or maintenance of 
this endocrine cell population [16]. Similar observations in the pancreas were also 
reported in Arx null mice in which a complete loss of α-cells was detected [2,19].  
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Without Arx function, α-cells are lost while β- and δ-cells simultaneously increase 
without a change in total endocrine mass [2].  Recently, lineage tracing of these Arx 
ablated α-cells has demonstrated that removal of Arx in glucagon+ cells results in 
conversion into an insulin+ β-like fate through a bihormonal intermediate [20].  
Interestingly, this conversion of α-cells into non-α-cell fates was only seen with loss of 
Arx during the neonatal period, not in adulthood [20]. 
Previous work has suggested a dual role for Arx in both specification of α-cells 
and repression of β- and δ-cell fate.  However, no studies have investigated the effects of 
the more common polyalanine expansion mutation on endocrine pancreas α-cell 
specification and maintenance.  Here we show that pancreatic defects associated with this 
Arx expanded mouse model (ArxE) are also context specific.  Our results demonstrate a 
reduced number of glucagon-expressing α-cells in ArxE pancreata, suggesting impaired 
α-cell specification.  However, a subset of α-cells is specified in ArxE mice and these 
cells do not express other hormones or β-cell specific transcription factors, indicating 
correct fate determination.  Conversely, maintenance of this subset of α-cells is impaired, 
and these cells are gradually lost through apoptosis over time.  Furthermore, unlike Arx 
null mutations, no change in β- or δ- cell mass is observed, suggesting that an expanded 
Arx protein is still capable of blocking other, non-α-cell fates.   
These results describe a unique pancreatic phenotype associated with an Arx 
polyalanine expansion mutation and further illustrate the genotype-phenotype correlation 
associated with different forms of ARX/Arx mutations.  Taken together, these findings 
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help elucidate our understanding of Arx-related syndromes outside of the brain as well as 
characterizing the different roles of Arx in α-cell specification versus maintenance. 
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Results 
ArxE mice retain a subset of glucagon-producing α-cells at embryonic day (E) 15.5. 
To determine the effect an Arx expansion mutation has on α-cell specification and 
maintenance, hemizygous ArxExpanded/Y (referred to as ArxE from here on) mutant mice 
were obtained by crossing heterozygous ArxExpanded/+ females to wild-type Arx+/Y males. 
ArxE mice were born in normal Mendelian ratios with birth weights similar to their 
littermate controls.  However, ArxE mice displayed a slower growth curve and by 
postnatal day 6 (P6) were significantly smaller than control littermates (Terry and May, 
unpublished data).  We did not observe any significant changes in pancreatic weight, 
morphology, or histology between ArxE mice and controls at any time point (data not 
shown). 
To explore a possible pancreatic defect, immunostaining was performed in control 
and ArxE pancreata at E15.5 to examine the presence, localization, and segregation of 
each endocrine hormone.  Immunostaining for glucagon demonstrated a dramatic 
reduction in the number of glucagon+ α-cells at E15.5 in ArxE mice (Fig. 4.1A-F).  
However, unlike Arx null animals, a subset of α-cells appeared to be specified in ArxE 
mice by glucagon staining [2,19].  Furthermore, these remaining glucagon+ cells did not 
coexpress insulin or somatostatin suggesting proper α-cell fate determination (Fig. 4.1A-
D).   Co-staining for glucagon and ghrelin did reveal 30% colocalization in both control 
and ArxE pancreata, similar to what has been previously described in wildtype pancreata 
(Fig. 4.1E-F) [21].  PP-cells are not normally present at E15.5 and immunostaining for 
  
119 
glucagon and PP did not reveal any precocious specification of this cell type in ArxE 
mice (data not shown) [17].  Consistent with our qualitative analysis, morphometric 
studies showed that while α-cell mass is significantly decreased to 20% of wild-type 
levels, no change in β- or δ-cell mass was observed (Fig. 1G).  Furthermore, total 
endocrine mass was not significantly altered at this time point.  
Although the endocrine mass of β- and δ-cells was not changed, we also measured 
the expression levels of the hormone genes in ArxE mice using quantitative PCR (qPCR).  
The expression level of glucagon was significantly reduced in ArxE pancreata, as 
expected (Fig. 1H).  However, both insulin and somatostatin transcript levels were 
significantly upregulated in ArxE pancreata when compared to littermate controls (Fig. 
4.1H).  No significant difference in the expression level of PP was observed in ArxE 
mice, further indicating that there was no precocious expression of PP upon ArxE 
mutation (Fig. 4.1H).  Since β- or δ-cell mass is not increased, our qPCR results suggest 
that there is a significant upregulation of hormone gene expression within the respective 
endocrine cells.  These data demonstrate that the majority of α-cell specification is 
impaired in ArxE mice but, for a subset of α-cells that are specified, fate determination 
appears intact without any misexpression of other endocrine hormone populations within 
the α-cells, unlike Arx null mouse models. 
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Figure 4.1: ArxE mice are able to specify a subset of α-cells at E15.5 
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Figure 4.1: ArxE mice are able to specify a subset of α-cells at E15.5. (A-F):  Control 
and ArxE E15.5 pancreatic sections were stained for glucagon (green) and insulin (red; 
A-B), somatostatin (Sst; red; C-D), and ghrelin (Ghr; red; E-F). Scale bar denotes 50µm. 
(G): Quantification of total endocrine (ChrgA) and β-, δ-, and α-cell mass in control 
(black bar) and ArxE (white bar) pancreata. (H): Quantification of transcript levels for 
each endocrine hormone in control (black bar) and ArxE pancreata (white bar) at E15.5 
using qPCR.  All results are graphed as fold change relative to littermate controls ± 
standard error of the mean. Significance is denoted with (*) when p<0.05.  All analysis 
consists of 4-5 animals per group.   
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By P14, the α-cell lineage is profoundly lost in ArxE pancreata 
 To determine the fate of this remaining subset of α-cells in ArxE mice, control 
and ArxE P14 pancreatic sections were examined for the expression of each endocrine 
population.  Morphometric analysis showed that α-cell mass is reduced by 99.5% with 
only a few single glucagon+ cells remaining (Fig. 4.2A-H, J). Immunostaining and 
quantification of β-, δ-, PP-, and ε-cell mass at P14 did not reveal any significant 
differences in quantity or localization of these endocrine cell types in ArxE mice (Fig. 
4.2A-I). Finally, we observed a significant 30% reduction in total endocrine mass in P14 
ArxE mice as measured by Chromogranin A staining (Fig. 4.2I).  This reduction is likely 
the result of the drastic loss of α-cells in the ArxE mice at this age.  These data suggest 
that α-cells are lost in ArxE mutant mice and not reallocated to a β- or δ-cell fate. 
To examine when the loss of the α-cell lineage occurs, we measured α-cell mass 
in embryonic and postnatal pancreata, starting at E15.5 (Fig.4. 2J).  As previously 
described, a subset of α-cells is properly specified in E15.5 ArxE pancreata; however, 
these cells are gradually lost over time.  From our morphometric analyses of E15.5, 
E18.5, P0 and P14 pancreata, we conclude that this α-cell population is not maintained, 
and is lost in a temporal manner without reallocation to a β- or δ-cell fate, resulting in a 
significant reduction in total endocrine cell mass. 
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Figure 4.2: ArxE mice have almost complete loss of α-cell fate by P14 with a 
concomitant decrease in total endocrine mass, but no change in β- and δ-cell mass 
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Figure 4.2: ArxE mice have almost complete loss of α-cell fate by P14 with a 
concomitant decrease in total endocrine mass, but no change in β- and δ-cell mass.  
(A-H): P14 pancreatic sections were stained for glucagon (green) and insulin (red; A-B), 
somatostatin (Sst; red; C-D), PP (red; E-F), and ghrelin (Ghr; red; G-H). Scale bar 
denotes 50µm.  (I): Quantification of endocrine hormone mass including total endocrine 
mass (ChrgA), insulin, somatostatin, PP, and ghrelin displayed as fold change in ArxE 
mice (white bar) relative to control (black bar). (J): Analysis of glucagon mass over time 
starting at E15.5 and ending at P14 in control (black bar) and ArxE (white bar) pancreata. 
Resulting p value is listed.  (*) denotes significance where p<0.05.  Error bars represent 
standard error of the mean (I, J).  For all analysis 4-5 animals per group were analyzed 
with all ArxE mice being males and control mice consisting of male and female mice. 
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ArxE α-cells do not express β-cell specific transcription factors  
To further examine whether α-cell specification is properly executed in ArxE 
pancreata, qPCR analysis was used to analyze the expression of α- and β-cell specific 
transcription factors in ArxE and control pancreata at E15.5. The α-cell specific 
transcription factors Arx and Brn4 were significantly downregulated in ArxE mice to 
approximately 30% of wild-type levels (Fig. 4.3A).  This downregulation is similar to the 
reduction in α-cell mass and is likely the result of having fewer α-cells expressing these 
transcription factors.  Strikingly, examination of β-cell specific factors MafA, Glut2, 
Pdx1, and Pax4 demonstrated a significant upregulation of MafA and Glut2 while Pdx1 
and Pax4 levels were not altered (Fig. 4.3A).  
To determine if the significant upregulation of MafA and Glut2 mRNA levels in 
ArxE mice results in misexpression of these factors in α-cells, immunostaining for 
glucagon, Pdx1, Glut2, and MafA was performed (Fig. 4.3B-G).  Similar to control 
animals, no colocalization of glucagon with Pdx1, Glut2, or MafA was observed in ArxE 
pancreata at E15.5 (Fig. 4.3B-G).  These data indicate that while an Arx expansion 
mutation results in upregulation of MafA and Glut2 transcript levels, this change does not 
lead to misexpression of the protein in ArxE E15.5 glucagon+ α-cells. When combined 
with previous results, this result indicates that α-cell fate determination has occurred 
normally in the remaining glucagon+ cells. 
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Figure 4.3: Specified α-cells in ArxE mice do not misexpress β-cell specific 
transcription factors at E15.5 
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Figure 4.3: Specified α-cells in ArxE mice do not misexpress β-cell specific 
transcription factors at E15.5.  (A): Quantification of transcript levels for α- and β-cell 
specific transcription factors graphed as fold change in ArxE pancreata (white bar) 
relative to littermate control (black bar).  Error bars represent standard error of the mean. 
Significance, when p≤0.05, is denoted with (*).  (B-G): Control and ArxE E15.5 
pancreatic sections were stained for glucagon (green) and Pdx1 (red; B-C), Glut2 (red; D-
E), and MafA (red; F-G). Five specimens were analyzed for each group and 
representative images taken.  (*) denotes autofluorescence of red blood cells. Scale bar 
denotes 50µm.  
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ArxE pancreata contain more apoptotic glucagon+ cells  
 There are two possible causes for the apparent loss of α-cells in ArxE pancreata: 
reduced proliferation or increased apoptosis.  Proliferation was measured by examining 
the localization and quantity of proliferating glucagon+ α-cells using the proliferation 
marker Ki67.  No change in the number of proliferating, Ki67+ α-cells was noted in ArxE 
mice when compared to control littermates at E15.5 (Fig. 4.4A-B).  Furthermore, 
expression analysis using qPCR for Ki67 and Birc5 (another proliferation marker) did not 
reveal any differences in the expression level between control and ArxE pancreata (Fig. 
4.4C).  These data demonstrates that α-cells proliferate normally in ArxE mice at E15.5.  
 To explore whether changes in the rate of apoptosis may have contributed to α-
cell loss we performed TUNEL assays.  Co-immunostaining for glucagon and TUNEL 
demonstrated an increase in the number of TUNEL+/glucagon+ cells in ArxE pancreata at 
E15.5 (Fig. 4.4D-E).  Quantification of the percentage of glucagon+ that were TUNEL+ in 
control and ArxE pancreata demonstrated a significant and profound increase in the 
percent apoptotic α-cells in ArxE pancreata (Fig. 4.4F).  Taken together, these results 
demonstrate that an increase in apoptosis is the major contributor to the temporal α-cell 
loss seen in ArxE pancreata.   
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Figure 4.4: There is a drastic increase in the percentage of apoptotic glucagon+ cells 
in ArxE mice, but no apparent change in proliferation 
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Figure 4.4: There is a drastic increase in the percentage of apoptotic glucagon+ cells 
in ArxE mice, but no apparent change in proliferation.  (A-B): Control and ArxE 
E15.5 pancreatic sections were stained for glucagon (green) and Ki67 (red). Scale bar 
denotes 50µm.  (C): qPCR analysis for two markers of proliferation, Ki67 and Birc5, in 
E15.5 control (black bar) and ArxE pancreata (white bar).  Results are graphed as fold 
change relative to littermate control ± the standard error of the mean. (D-E): Control and 
ArxE E15.5 pancreatic sections were stained for glucagon (green) and TUNEL (red). 
Arrow points to TUNEL+ cell.  Scale bar denotes 10µm. (F): Quantification of the 
percentage TUNEL+glucagon+ cells over total counted glucagon+ cells in control and 
ArxE E15.5 pancreatic sections.  All glucagon+ cells in five different pancreatic sections 
from both control (black bar) and ArxE (white bar) mice were counted and determined to 
be TUNEL positive or negative. The percentage of TUNEL+glucagon+ cells was 
calculated and graphed as ± standard error of the mean.  (*) denotes significance where 
p≤0.05. Between 4 and 5 animals were examined per group for each analysis.  
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Discussion 
This study demonstrates that expansion of the first polyalanine tract of Arx results 
in impaired specification and maintenance of endocrine α-cells through a mechanism of 
programmed cell death, as opposed to α-cell fate re-specification. We show that only a 
subset (20%) of α-cells is present in E15.5 ArxE pancreata.  However, these glucagon+ α-
cells are not maintained over time and eventually undergo apoptosis, leading to a 
complete absence of the α-cell lineage and a significant decrease in total endocrine cell 
mass by P14.  While cell proliferation is a major mechanism to expanding α-cell mass 
during development, we did not detect a significant change in the rate of proliferation in 
ArxE pancreata.  These findings suggest that programmed cell death is the principal 
cause, after initial specification, for α-cell loss in ArxE mice (Fig. 4.5).   
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Figure 4.5: ArxE mice are able to correctly specify a subset of α-cells, but α-cells are 
gradually lost through apoptosis 
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Figure 4.5: ArxE mice are able to correctly specify a subset of α-cells, but α-cells are 
gradually lost through apoptosis.  Model demonstrating normal proliferation, but 
increased apoptosis in ArxE mice.  Normal proliferation during embryonic time points 
maintains the α-cell lineage by replacing cells lost to apoptosis. However, proliferation 
slows during the neonatal stage leading to loss of the α-cell lineage. 
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ArxE mice reveal context specific defects in α-cells that differ from Arx null mice. 
  Our study reveals a novel and unique impact of ArxE mutations on the pancreas.  
Phenotypes found in ArxE mice differ from those reported in the Arx null mouse models: 
1) there is no change in β- and δ-cell mass, 2) there is a significant reduction in total 
endocrine cell mass, and 3) a small number of α-cells are present during embryogenesis 
[2].  Arx null mutations result in loss of α-cell specification in which glucagon+ cells are 
never present, even at embryonic time points [2].  Loss of Arx in these endocrine 
progenitors results in loss of specification and reallocation of these cells into a β- or δ-cell 
fate, thus maintaining total endocrine mass [2].  Conversely, ArxE mice are able to 
specify a small subset of α-cells and, more importantly, repress non-α-cell fates, 
including β and δ.  This retained repressive ability results in normal β- and δ-cell mass 
even with the eventual complete loss of the α-cell lineage.  Finally, α-cells in ArxE mice 
are not able to maintain their fate, as these α-cells are gradually eliminated over time 
through apoptosis, not reallocation or reprogramming, resulting in an overall decrease in 
endocrine cell mass.  
 
ArxE mice display selective derepression similar to previous neuronal studies.  
 Cell culture based mechanistic studies have demonstrated that Arx associates with 
the groucho-family corepressor Tle1 [22].  This association is carried out through Arx’s 
octapeptide domain and results in increased repressive activity [22].  Examination of this 
association in an expanded neuronal model demonstrates a decreased, but not complete 
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loss, of Arx-Tle1 protein binding [23].  Furthermore, neuronal studies have demonstrated 
that expansion of the first polyalanine tract of Arx results in selective derepression of a 
subset of Arx targets [23].  It is hypothesized that loss of association with specific co-
repressors (if not Tle1 itself) results in this selective derepression [23].  Interestingly, we 
show here that ArxE mice do not misexpress either the endocrine hormones insulin and 
somatostatin or β-cell specific transcription factors in embryonic α-cells.  Thus, it appears 
that at least part of Arx’s repressive abilities are intact.   Future studies using chromatin 
immunoprecipitation to determine direct targets of Arx in the pancreas will serve to 
clarify this finding.  The increased expression of insulin, somatostatin, and β-cell markers 
are in the cells where Arx is not expressed, suggesting a secondary effect. 
 
Comparing ArxE and Arx null mouse models demonstrate a direct genotype-phenotype 
correlation.  
 In neuronal studies, there appears to be a direct genotype-phenotype correlation 
associated with various Arx mutations [24].  Our study demonstrates that this correlation 
is likely to be applicable in the pancreas as well.  In the brain, more severe phenotypes 
are attributed to null and missense mutations of Arx [8].  In the pancreas, the Arx null 
mutation has an earlier onset with complete loss of glucagon-expressing α-cells [2].  
Although the α-cell population is almost completely lost by P14 in the ArxE mice, their 
survival curve compared to the global null mice is improved.  It is difficult to determine 
if this improved survival can be attributed to the pancreatic phenotype without a tissue-
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specific model.  Although it has been suggested that hypoglycemia is the cause of early 
fatality, blood sugar levels cannot be attributed solely to the pancreas in the setting of 
diarrhea and lean body mass in the ArxE mouse model (Terry and May, unpublished 
data).  Complete understanding at a molecular level of why this spectrum of disease 
exists in both mouse models and human patients will be essential in generating future 
treatments for patients with ARX-related disorders. 
 
Conclusion 
 In conclusion, this study demonstrates dual functions for Arx in α-cell gene 
activation and β-cell gene repression during fate specification and maintenance.  Utilizing 
a mouse model with an expansion mutation of the first polyalanine tract of Arx, we 
demonstrate present but impaired α-cell fate specification.  Although α-cell number is 
dramatically reduced, proper fate determination is observed in the remaining α-cells. 
However, these cells eventually undergo apoptosis, which leads to complete loss of α-cell 
fate postnatally. β- or δ-cell mass is not increased, and there is a significant decrease in 
total endocrine cell mass, attributed to α-cell death. Our study begins to explore the more 
common polyalanine expansion, non-null Arx mutations and the effect they have on α-
cell specification and maintenance.  Being able to separate the dual function for gene 
activation and gene repression leading to fate specification and maintenance will lead to a 
better understanding of the clinical presentation of ARX-related disorders and help in 
designing future therapeutic treatments.   
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Materials & Methods 
Ethics Statement  
The Children’s Hospital of Philadelphia’s Institutional Animal Care and Use Committee 
(IACUC) approved all animal experiments under the protocol number 2011-10-756. 
CLM monitored all animal studies. 
Animals and Breeding Strategy  
The derivation of mice with an expansion mutation in the first polyalanine tract of Arx 
has been described previously [15]. Since Arx is located on the X chromosome 
ArxExpanded (E)/+ females were bred to Arx+/Y males to generate ArxE/Y mutant males and 
ArxE/+, Arx+/+, and Arx+/Y control females and males, respectively.  Above controls, both 
males and females, were physiologically indistinguishable in all aspects examined and as 
such were used interchangeably. Mice were mated on a C67BL/6 background.  The 
Children’s Hospital of Philadelphia’s Institutional Animal Care and Use committee 
approved all experiments. 
Immunohistochemistry and Histology 
All dissections were performed in cold 1X PBS.  Entire pancreatic tissue was removed, 
weighed, and submerged in cold 4% PFA/PBS overnight.  Tissues were rinsed in PBS, 
dehydrated, embedded in paraffin, and sectioned at 8µm.  Antigen retrieval was 
performed in 10mmol citric acid buffer (pH 6.0) followed by blocking of endogenous 
peroxidase and avidin/biotin activity with 3% H2O2 (Sigma) and avidin/biotin blocking 
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kit (Vector), respectively.  Slides were incubated in primary antibody overnight at 4°C.  
Primary antibodies used were: Glucagon (GP 1:3000, Millipore and Rb 1:1000, 
Chemicon), Insulin (MS 1:400, Thermo Scientific and GP 1:1000, Abcam), PP (Rb 
1:200, Invitrogen), Sst (Rb 1:200, Invitrogen), Ghrelin (Gt 1:200, Santa Cruz), Pdx1 (Gt 
1:200, Santa Cruz), MafA (Rb 1:1000, Bethyl), Glut2 (Rb 1:1000, Millipore), and 
Chromogranin A (Rb 1:3000, DiaSornin). Appropriate secondary antibodies were added 
at room temperature (Vector Laboratories).  For immunofluorescence, secondary 
antibodies were conjugated to either Cy2 or Cy3 (Jackson Laboratories) while 
immunohistochemical detection was obtained with the VECTASTAIN ABC kit and 
diaminobenzidine tetrahydrocholoride (DAB) substrate (Vector Laboratories).  All 
images utilized in this study were obtained using a Leica DM6000B microscope. 
Real-Time PCR Analysis 
For expression analysis, whole pancreatic tissue was dissected in cold 1X PBS and 
homogenized in 1mL TRIZOL reagent (Invitrogen). RNA was isolated using provided 
protocol and cDNA synthesized using Oligo-dT, Superscript, and additional necessary 
reagents (Invitrogen).  All quantitative PCR (qPCR) analysis was conducted in duplicate 
for each specimen including at least three biologic replicates for control and mutant 
analyzed with reference dye normalization.  qPCR analysis was performed using Brilliant 
SYBR Green PCR Master Mix (Agilent) in the Stratagene Mx3005P Real-time PCR 
machine.  Changes in expression level were determined by calculating and graphing fold 
change relative to control. Primer sequences are available upon request.  
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Hormone Cell Quantification 
Total endocrine and hormone cell mass was calculated through the use of Aperio 
Software.  Two sections per animal were used with four or five animals per group (both 
control and ArxE) analyzed.  Sections were stained for either hormone mass (glucagon, 
insulin, somatostatin, PP, and ghrelin) or total endocrine mass (ChrgA) using 
immunohistochemistry.  After dehydration and mounting, slides were scanned into the 
Aperio software and positive hormone area and total pancreatic area determined. 
Hormone mass and total endocrine mass was than calculated using pancreatic weight.  
All ArxE mice were males while control specimens consisted of male and female mice 
(see animal breeding section above).  No difference in hormone or total endocrine mass 
was seen between any of the controls utilized. 
Statistical Analysis 
Error bars were determined as ± standard error of the mean (SEM) and all values are 
displayed as ± SEM.  Significance was determined using a two-tailed Student’s t-test and 
results considered significant when p ≤ 0.05.   
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Chapter V: 
Conclusions and Future Directions 
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Conclusions 
 Type II diabetes mellitus is a global health crisis [1].  Current therapies for this 
disease, the majority of which attempt to control blood glucose levels through exogenous 
insulin administration, only address the most immediate consequences of inadequate 
insulin signaling [1]. Long-term therapies that restore endogenous blood glucose 
homeostasis will provide patients with better control of their condition while vastly 
improving quality of life [1].  One of the most attractive long-term therapies is 
transdifferentiation of endogenous pancreatic endocrine α-cells into physiologically 
functional β-cells [2].   
This treatment option stems from the novel bihormonal view of diabetes, which 
posits that both decreased insulin action and hyperglucagonemia contribute to 
hyperglycemia [3].  Transdifferentiation of α- to β-cells would alleviate both of these 
pathological issues by increasing β-cell numbers and insulin secretion while 
simultaneously decreasing α-cell numbers and glucagon secretion.  This therapy will 
provide patients with long-term endogenous control of blood glucose levels and eliminate 
the need for exogenous insulin administration [3]. 
 In order to develop novel α- to β-cell replacement therapies to treat diabetes, a 
complete understanding of normal α-cell development and maintenance is essential [3].  
Previous studies have demonstrated the key roles transcription factors play in endocrine 
cell fate specification and maintenance [1].  Knowledge of the involvement of these 
factors can be utilized to manipulate α-cells in designing an effective protocol for future 
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therapies [1].  My dissertation attempted to broaden knowledge of normal α-cell 
specification and maintenance by examining the multi-faceted roles of the homeodomain 
containing transcription factor Arx.  Previous studies have demonstrated that Arx is 
necessary and sufficient for α-cell specification [4,5].  However, the role of Arx in 
maintenance of α-cell fate, as well as the processes that are impacted by non-null Arx 
mutations during α-cell development, has not been examined.   
In Chapter 2, I examined the role of Arx in maintenance of α-cell fate.  I 
demonstrated that ablation of Arx in glucagon+ cells during development results in loss of 
proper cell fate maintenance and conversion into a β-like-cell through a glucagon+insulin+ 
bihormonal intermediate. By P21 the majority of Arx-ablated α-cells were only insulin+, 
suggestive of transdifferentiation to a β-cell fate.  Many of these newly converted cells 
also expressed other β-cell markers, including MafA, Glut2, and Pdx1.  Conversely, 
short-term ablation (2 weeks) of Arx in adult mice does not result in loss of endocrine α-
cells or misexpression of other endocrine hormones.  These data determined that Arx is 
necessary for neonatal α-cell fate maintenance, but not for short-term cell fate 
maintenance in the adult. 
I expanded on these results in Chapter 3, in which I explored the impact of a long-
term ablation of Arx in mature α-cells using a global, tamoxifen-inducible, transgenic 
mouse model.  This long-term study demonstrated that eight weeks after Arx ablation, 
mutant mice had an improved glucose tolerance and had lost weight compared to 
littermate controls.  Pancreatic analysis revealed that while normal numbers of glucagon+ 
cells are present in mutant mice, many α-cells co-express other endocrine hormones, 
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including insulin and PP, but not somatostatin.  Additionally, insulin and glucagon 
secretion studies demonstrated loss of glucagon secretion and content, as well as 
improper insulin secretion in response to both α- and β-cell stimuli.  When taken 
together, these data determined that although Arx-ablated α-cells are capable of 
maintaining glucagon expression, over time these cells lose their identity and become an 
α-β hybrid cell. These hybrid cells expressed both α- and β-cell hormones, but only 
secreted insulin in response to α- or β-cell stimuli, indicative of a transdifferentiation-like 
process.   
Finally, in Chapter 4 I explored the effect non-null Arx mutations have on proper 
α-cell specification and maintenance.  Using a knock-in mouse model with an expansion 
mutation in the first polyalanine tract, I determined that pancreatic α-cell development is 
severely impaired in these mice.  However, unlike Arx null mutations, a subset of α-cells 
are specified and do not misexpress other endocrine hormones or β-cell specific 
transcription factors, indicating correct α-cell specification and repression of non-α-cell 
fates.  This subset of α-cells subsequently undergoes apoptosis, and the α-cell lineage is 
lost by P14, along with a significant reduction in total endocrine mass.  Together, these 
studies suggest that Arx plays a dual role during α-cell specification through both 
repression of non-α-cell fates and activation of α-cell fate.  An expansion mutation of Arx 
results in loss of activation of α-cell fate (only a subset of α-cells specified), but not 
repression of non-α-cell fates (no misexpression of β-cell-specific hormones or proteins). 
 
  
147 
  
  
148 
Future Directions 
What are the cellular differences between neonatal and adult endocrine cells? 
 Numerous studies show that complete maturation of β-cells occurs during the first 
two weeks of life [6].  Before and during this period insulin-producing β-cells are 
classified as immature and cell fate is more plastic [6]. After weaning (P21) and 
maturation of β-cells is complete, cell fate is more defined and cells are less likely to 
convert into other cell types [6].  The end of this period is marked by the loss of MafB 
and gain of MafA expression in the mature β-cell [7].   
 Since pancreatic endocrine cells have a common lineage, a similar maturation 
period seems likely in endocrine α-cells [8].  I demonstrated phenotypic differences 
between ablation of Arx in neonatal versus adult α-cells.  These observed differences 
could be attributed to immature versus mature α-cells and the associated plasticity in cell 
fate.  These data also correlate with a study examining misexpression of Pdx1 in α-cells 
during late development and in mature α-cells [9].  Misexpression of Pdx1 in "immature" 
α-cells led to transdifferentiation into β-cells [9].  However, misexpression of Pdx1 in 
mature α-cells did not result in such a conversion [9]. 
 When taken together, these studies suggest that cell fate maintenance is different 
in neonatal versus adult α-cells.  Future studies identifying differentially expressed 
transcription factors will begin to characterize each state.  Further experiments ablating 
transcription factors at diverse time points will aid in mapping the maturation process for 
endocrine α-cells. 
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Likely, chromatin marks and histone modifications play an important role in this 
maturation process [10].  A situation can be imagined in which newly formed endocrine 
cells are largely devoid of lineage-specific histone modifications and thus more plastic.  
However, over time histone modifications are added, making cell fate more defined and 
the cell mature.  Previous studies have demonstrated an extensive landscape of activating, 
repressing, and bivalent chromatin marks in mature α-cells [11]. Furthermore, loss of 
normal DNA methylation in mature β-cells leads to loss of cell fate, derepression of Arx, 
and conversion into an α-cell fate [12].  Experiments examining histone modifications 
and other chromatin marks will determine the nature of these marks, if there are 
differences throughout the maturation process, and if these differences correlate with 
maturing α-cells. α-cell specific characterization and ablation of each mark during 
development as well as in mature α-cells will greatly clarify this issue. 
 
Does Arx play multiples roles in specification and maintenance of α-cells? 
Using a mouse model with an expansion mutation in the first polyalanine tract of 
Arx, I demonstrated a reduced, but present, pancreatic α-cell population.  α-cell 
specification appears correct, with no misexpression of other endocrine hormones or β-
cell transcription factors.  These data suggest that Arx plays a dual role during 
specification in which it not only activates α-cell fate, but also leads to repression of other 
non-α-cell fates.  While an expanded form of Arx is not able to allocate normal numbers 
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of α-cells (activation of α-cell fate), it is able to repress non-α-cell fates, resulting in 
proper specification of a subset of α-cells. 
 Future experiments utilizing other non-null mutations of Arx that differentially 
affect α-cell function will help clarify and elucidate these roles.  Human neuronal studies 
have classified a wide range of Arx mutations that differentially affect Arx's functional 
abilities during neuronal development [13].  Exploring these mutations and the resulting 
pancreatic phenotypes will further elucidate the role(s) of Arx during α-cell development.  
In addition, chromatin immunoprecipitation (ChIP) experiments are essential to identify 
direct targets of Arx.  Since Arx predominantly functions as a repressor, and is also 
thought to repress β-cell fate, likely targets include β-cell specific transcription factors, 
such as Pdx1 and Pax4 [14,15]. These ChIP experiments will determine if each role of 
Arx is due to direct repression/activation of Arx at a gene promoter or the indirect result 
of Arx activity in endocrine α-cells. Finally, co-immunoprecipitation experiments will 
determine if Arx is interacting with other co-repressors to exert its transcriptional 
regulation in endocrine progenitors and newly created α-cells.  Neuronal studies have 
demonstrated Arx association with the co-repressors Tle1 and CtBP, leading to increased 
transcriptional repression ability [14,16].  Studies examining these potential associations 
during endocrine development will determine their role in the specification of α-cells.  
Together, these experiments will clarify the function and mechanism(s) of Arx during α-
cell development. 
 Once the role(s) of Arx during α-cell development is understood, this knowledge 
can be expanded to the role of Arx in maintenance of α-cell fate.  My data demonstrate 
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that Arx is necessary for α-cell fate maintenance.  It would be interesting to explore the 
targets and co-factors of Arx in the adult α-cell and determine if they are similar during 
embryogenesis and postnatal life, or if there are important changes.  This knowledge 
would illustrate key differences between neonatal and mature α-cell fate maintenance.  
Factors expressed in mature α-cells, but not during development, are likely to be 
important in maintenance of cell fate.  These studies will help expand the knowledge of 
Arx in α-cells as well as how the endocrine pancreas is specified and maintained in 
general.   
 
Novel therapies for Type II Diabetes utilizing Arx in α-cells 
 During embryogenesis, endocrine cells are plastic and immediately lose cell fate 
upon disruption of the proper transcriptional program [15].  However, as these cells 
mature they become less plastic, and disruptions in the transcriptional program do not 
immediately result in striking phenotypes [17].  In line with this, ablation of Arx in 
mature α-cells does not result in a rapid or complete loss of α-cell fate.  Instead, Arx-
ablated α-cells appear to slowly lose cell identity and take on an α-β-cell hybrid fate that 
secretes insulin in response to both α and β stimuli.  Other cellular processes may make it 
difficult for mature α-cells to quickly and completely abandon their determined cell fate. 
Previous studies have illustrated the extensive chromatin landscape in mature α-cells 
[18].  This landscape, combined with the normal transcriptional program, likely maintains 
cell fate even upon transcriptional disruptions. 
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 Novel therapies for type II diabetes could emphasize decreased Arx expression 
combined with additional stimuli to transdifferentiate mature α-cells into functional, 
physiologically correct β-cells.  Previous studies have demonstrated that upon total 
ablation of β-cells, mature α-cells can spontaneously convert into functional β-cells [19].  
Future experiments combining ablation of Arx with other pancreatic stressors or ablation 
of chromatin marks would extend the observed adult phenotype and bring the field closer 
to innovative treatments for type II diabetes.  Furthermore, these experiments will extend 
the field's knowledge of cell fate maintenance and its limits. 
 
Summary 
 The goal of this dissertation was two-fold: (1) to determine the role of Arx in 
maintenance of neonatal and mature endocrine α-cells, and (2) to characterize the effect 
of a non-null polyalanine expansion mutation on normal α-cell specification and 
maintenance.  Overall, these results expand the previously described role of Arx in the 
early specification of α-cells.  The data presented here demonstrate that Arx is also 
necessary for maintenance of α-cell fate, and plays a dual role during specification 
through the activation of α-cell fate and repression of non-α-cell fates. 
 Together these studies significantly contribute to the field in multiple ways.  First, 
I demonstrated a novel role for Arx in α-cell fate maintenance, which can be utilized for 
novel treatments of type II diabetes.  Additionally, the discovery of dual roles for Arx 
during α-cell specification raises the possibility that additional transcription factors are 
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playing similar roles in other endocrine cell types.  Finally, the loss of α-cell fate 
maintenance during long-term ablation of Arx demonstrates that while mature pancreatic 
islet cells may be able to function normally in the short-term upon loss of Arx, over time 
even mature endocrine cells can lose their cell identity.  Overall, these data expand the 
field’s knowledge regarding normal α-cell specification and maintenance, and provide an 
attractive avenue for future transdifferenation studies to develop novel treatments for type 
II diabetes. 
References: 
1. Guo T, Hebrok M (2009) Stem cells to pancreatic beta-cells: new sources for diabetes 
cell therapy. Endocrine reviews 30: 214-227. 
2. Borowiak M, Melton DA (2009) How to make beta cells? Current opinion in cell 
biology 21: 727-732. 
3. Quesada I, Tuduri E, Ripoll C, Nadal A (2008) Physiology of the pancreatic alpha-cell 
and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol 
199: 5-19. 
4. Collombat P, Mansouri A, Hecksher-Sorensen J, Serup P, Krull J, et al. (2003) 
Opposing actions of Arx and Pax4 in endocrine pancreas development. Genes 
Dev 17: 2591-2603. 
5. Collombat P, Hecksher-Sorensen J, Krull J, Berger J, Riedel D, et al. (2007) 
Embryonic endocrine pancreas and mature beta cells acquire alpha and PP cell 
phenotypes upon Arx misexpression. J Clin Invest 117: 961-970. 
6. Aye T, Toschi E, Sharma A, Sgroi D, Bonner-Weir S (2010) Identification of markers 
for newly formed beta-cells in the perinatal period: a time of recognized beta-cell 
immaturity. The journal of histochemistry and cytochemistry : official journal of 
the Histochemistry Society 58: 369-376. 
7. Hang Y, Stein R (2011) MafA and MafB activity in pancreatic beta cells. Trends in 
endocrinology and metabolism: TEM 22: 364-373. 
8. Gu G, Dubauskaite J, Melton DA (2002) Direct evidence for the pancreatic lineage: 
NGN3+ cells are islet progenitors and are distinct from duct progenitors. 
Development 129: 2447-2457. 
9. Yang YP, Thorel F, Boyer DF, Herrera PL, Wright CV (2011) Context-specific alpha- 
to-beta-cell reprogramming by forced Pdx1 expression. Genes Dev 25: 1680-
1685. 
10. Clee SM, Attie AD (2007) The genetic landscape of type 2 diabetes in mice. 
Endocrine reviews 28: 48-83. 
  
154 
11. Bramswig NC, Kaestner KH (2011) Transcriptional regulation of alpha-cell 
differentiation. Diabetes Obes Metab 13 Suppl 1: 13-20. 
12. Dhawan S, Georgia S, Tschen SI, Fan G, Bhushan A (2011) Pancreatic beta Cell 
Identity Is Maintained by DNA Methylation-Mediated Repression of Arx. Dev 
Cell 20: 419-429. 
13. Friocourt G, Parnavelas JG (2010) Mutations in ARX Result in Several Defects 
Involving GABAergic Neurons. Front Cell Neurosci 4: 4. 
14. McKenzie O, Ponte I, Mangelsdorf M, Finnis M, Colasante G, et al. (2007) 
Aristaless-related homeobox gene, the gene responsible for West syndrome and 
related disorders, is a Groucho/transducin-like enhancer of split dependent 
transcriptional repressor. Neuroscience 146: 236-247. 
15. Collombat P, Hecksher-Sorensen J, Serup P, Mansouri A (2006) Specifying 
pancreatic endocrine cell fates. Mech Dev 123: 501-512. 
16. Fullenkamp AN, El-Hodiri HM (2008) The function of the Aristaless-related 
homeobox (Arx) gene product as a transcriptional repressor is diminished by 
mutations associated with X-linked mental retardation (XLMR). Biochem 
Biophys Res Commun 377: 73-78. 
17. Juhl K, Bonner-Weir S, Sharma A (2010) Regenerating pancreatic beta-cells: 
plasticity of adult pancreatic cells and the feasibility of in-vivo neogenesis. 
Current opinion in organ transplantation 15: 79-85. 
18. Bramswig NC, Everett LJ, Schug J, Dorrell C, Liu C, et al. (2013) Epigenomic 
plasticity enables human pancreatic alpha to beta cell reprogramming. The 
Journal of clinical investigation 123: 1275-1284. 
19. Thorel F, Nepote V, Avril I, Kohno K, Desgraz R, et al. (2010) Conversion of adult 
pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 464: 1149-
1154. 
 
